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ABSTRACT 
A review of patients who underwent a hydrogen breath test for Small Intestinal 
Bacterial Overgrowth, following an oesophagectomy or gastrectomy was 
carried out in the Gastrointestinal Function Unit, St. James’s Hospital, Dublin. 
The aim of this research was to look at the incidence of Small Intestinal 
Bacterial Overgrowth and create an optimal protocol for Hydrogen Breath 
Testing with the hope of improving patient compliance and reducing clinic 
waiting times. Factors such as lifestyle, multimodal therapy, tumour 
morphology, and gender were analysed in relation to positive Hydrogen 
Breath Test results in this patient group. Patients were selected following a 
referral from the upper GI Surgical team. Exclusion criteria included those 
patients whom had complicated upper major GI surgery, those patients that 
had their surgery for a non-malignant carcinoma, and those patients that had 
their surgery for achalasia or a gastric fistula. 
Following a strict 12 hour fast and following pre-procedure instructions, the 
patient’s hydrogen breath test was conducted. A preliminary mouth rinse with 
a chlorhexadine agent was performed followed by a baseline breath sample. 
A solution of glucose or fructose was consumed and samples were taken 
every 15 minutes over a two hour period. The patient performed this 
manoeuvre by holding their breath for approximately 10 seconds and exhaling 
into the Gastro+ Gastrolyzer® breath monitor. Values were measured in parts 
per million. 
Poor lifestyle factors did not have an effect on the outcome of Hydrogen 
Breath Test results. Those patients who had a history of previous malignancy 
and post-operative complications showed a higher tendency towards a 
positive glucose Hydrogen Breath Test result as did those patients who had a 
longer post-operative hospital stay. This however, was not statistically 
significant.  The percentage of patients who were positive for Small Intestinal 
Bacterial Overgrowth (53% in total) was greatest 6-12 months post-surgery.  
This may be attributed by the fact that intestinal motility including Migrating 
Motor Complexes can take up to 12 months before it is restored to its normal 
functioning state. The positive patient group tested using glucose substrate 
demonstrated a 93% positivity for SIBO at 60 minutes. Therefore, this 
suggests that altering the protocol of testing from 2 hours to 60 minutes 
should be considered 
Some patients (up to 10%) are non-hydrogen producers, those who are very 
symptomatic with negative Hydrogen Breath Tests should be considered for 
bile acid malabsorption investigation using SeHCAT (tauroselcholic [75 
selenium] acid). SeHCAT is now available in St. James’s hospital to 
investigate patients who are symptomatic with steatorrhoea/diarrhoea post-
surgery. Small Intestinal Bacterial Overgrowth can be the cause of bile acid 
malabsorption, therefore it should be considered to treat it with antibiotic 
therapy and assess clinical response before commencement with prescribed 
bile acid sequestrants. 
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Chapter 1 
1 Introduction 
 
Hydrogen Breath Testing (HBT) is a technique that is directly and 
instantaneously capable of detecting both small intestinal bacterial overgrowth 
(SIBO) and dietary malabsorption. It is a simple and non-invasive procedure 
with few cost implications. The patient attends the Gastrointestinal Function 
unit after adhering to strict pre-procedure guidelines and the specific substrate 
(glucose, lactulose, or fructose) dissolved in 250mls of water is consumed. 
The patient is asked at regular intervals of 15 minutes to exhale into the 
Gastro+ Gastrolyzer® (Gastro+ Operating Manual 2014) HBT machine and a 
direct read out of Hydrogen in exhaled breath is measured in units of parts per 
million (ppm). Depending on the values obtained and the substrate consumed, 
this procedure can take from 90-180 minutes to perform. 
Small intestinal bacterial overgrowth, malabsorption of Lactose, Sucrose and 
Fructose, and Intestinal transit time using Lactulose can all be measured 
using the HBT. Glucose and Lactulose are the most commonly documented 
substrates used for detecting SIBO (Simren and Stotzer 2006). 
Small intestinal bacterial overgrowth (SIBO) is as the name suggests a 
bacterial overgrowth within the small intestine. Normally, anaerobic colonic 
bacteria reside in the large intestine and perform multiple functions to regulate 
the digestive system. Sometimes, conditions within the gastrointestinal (GI) 
tract prohibit the defence mechanism to prevent and keep bacterium from 
colonising within the small intestine. This may include elevated pH within the 
stomach, dysrhythmic activity altering the intestinal motility, or following GI 
surgery (DiBaise 2008). 
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When SIBO is present, the bacteria compete with the normal digestive 
process and affect the method in which nutrients pass across the lumen of the 
small intestine. The bacteria essentially ‘eat’ the nutrients (particularly 
carbohydrates and sugars) entering the intestine and produce by-products as 
a result. These include gases such as carbon dioxide and hydrogen, and 
short-chain fatty acids (Eisenmann et al 2008). It is these by-products that can 
cause unpleasant abdominal and GI symptoms such as bloating, flatulence, 
epigastric and abdominal pain, nausea, early satiety, and altered bowel habit. 
Patients who complain of such symptoms are often referred to have SIBO 
investigations performed.  
The rate of positive results in the GI function unit when testing for SIBO, is 
overall quite low. During a data analysis of procedures performed over a two 
year period, one group of patients with a high positive result for SIBO was 
evident. This was a surgical group of patients who was referred to the GI 
function unit post oesophagectomy or gastrectomy that were now complaining 
of post-surgical symptoms such as those described above in conjunction with 
malabsorption issues.  
The HBT does not impose any discomfort or agitate the patient in any invasive 
or unwarranted way. Side effects are uncommon and would include those 
symptoms listed above i.e. the patients’ normal symptomatic response to 
SIBO. In rare circumstances, patients’ may experience dizziness, allergy-like 
reactions or tachycardia arrhythmias (Ledochowski M and Ledochowski E 
2008). The drawback of this investigation for the patient is the time it takes to 
perform this study, compliance with the pre-procedure instructions and 
travelling for their appointment.  
In response to the above results, a retrospective study was undertaken on 
post-surgical patients that were referred to the unit, to investigate the 
incidence of SIBO. The aim was to determine at what point might SIBO have 
developed in these patients; and whether factors such as neoadjuvant 
chemotherapy or radiotherapy, the location of cancer/tumour, previous history 
of carcinoma, or surgery on the GI tract influenced the development of SIBO. 
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A comprehensive data analysis of e.g. patient history, lifestyle, co-morbidity 
factors, complications post-surgery and hydrogen breath test results, was 
scrutinised to determine if there was a significant aspect or consequence that 
could result in a greater incidence of developing SIBO.  
Factors related to the optimal timing of HBT sampling in post-surgical patients 
were examined to determine at which point patients were most likely to show 
a positive result. The overall aim of the present study is to create an optimal 
protocol for HBT in patients following GI surgery. This is to include the time 
segments between sampling, so that crucial values of exhaled Hydrogen are 
not missed due to altered GI physiology. 
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Chapter 2 
2 Anatomy and Physiology 
2.1 Gastrointestinal Tract 
 
The GI system consists of the mouth, oral cavity, oesophagus, stomach, small 
intestine, large intestine, rectum and anus, refer to Figure 2-1. (Martini 2006). 
The liver and pancreas are associated digestive organs which produce and 
secrete digestive juices into the small intestine. 
 
Figure 2-1 - Anatomy of the GI Tract (Visionary Health 2014) 
The oesophagus consists of striated muscle in the proximal segment and 
smooth muscle in the distal two thirds. It is approximately 25 cm in length with 
two sphincters; the upper oesophageal sphincter (UOS) in the proximal 
oesophagus and the lower oesophageal sphincter (LOS) in the distal 
oesophagus. The function of sphincters is to control the direction of flow 
through the GI tract (Stendal 1997).  
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The stomach has five main functions; to act as a reservoir for ingested food, 
to mix and grind food, to chemically break down food, to kill ingested 
microbes, and to control the emptying of gastric contents into the duodenum. 
The stomach has a number of important functions as described in Table 2-1 
overleaf. 
The motility of the stomach and small intestine differs depending on whether a 
person is fasting or has eaten recently. Migrating motor complexes (MMC) are 
the dominant pattern in the fasting state. Following ingestion of a meal, MMC 
are replaced by peristaltic and segmenting and mixing waves (DLGIP 2009). 
The pacemaker located on the greater curvature (refer to Figure 2-2) of the 
corpus of the stomach generates electric impulses for gastric motility. These 
are intense contractions that encourage mixing and grinding of solid food. 
There is a lag phase of about 30-60 minutes after eating before food is 
emptied into the duodenum. 
 
Figure 2-2 - Regions of the Stomach 
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Table 2-1 - Function of the main regions of the stomach 
Region Function  
Cardia Joins stomach and oesophagus 
Fundus Main Reservoir where ingested food is received 
Corpus 
HCL and pepsin produced here as well as fundus. Pacemaker 
area of stomach is located on the greater curvature of corpus 
Antrum 
Hormone gastin is produced here. There is no HCL secretion in 
this part. Principal site where solid food particles are ground 
down before emptied into duodenum 
Pylorus 
Controls emptying of food into duodenum and limits regurgitation 
of duodenal contents back into stomach. 
 
The small intestine is approximately 3-5m in length and consists of the 
duodenum, jejumum and ileum. The main function of the small intestine is the 
digestion and absorption of nutrients. This is implemented through (1) the 
mixing of food with digestive juices secreted into the intestinal lumen (2) 
ensuring the products of digestion come into contact with the absorptive 
surface of the small intestine and (3) to propel any waste products towards the 
colon (Stendal 1997). The duodenum is the most proximal portion of the small 
intestine. It is also the shortest part and extends from the pylorus, around the 
head of the pancreas and down to the jejunum. The common bile and 
pancreatic duct which open into the duodenum, allow bile and pancreatic 
juices to enter this portion of the intestine. The sphincter of Oddi controls the 
release of these digestive juices into the duodenum (Stendal 1997).   
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The colon has many functions, the most important of which are; the 
absorption and secretion of certain electrolytes and water, and the storage 
and excretion of waste (Gibson and Roberfroid 1995). The large intestine is 
approximately 1.3m in length and consists of the cecum with its appendix, 
ascending, transverse, descending and sigmoid colon (Stendal 1997).  The 
ileocecal valve is at the junction of the ileum and cecum and prevents 
retrograde movement of colonic contents back into the small intestine. It also 
regulates entry of small intestinal content into the colon. 
The colon at birth is a sterile, dark, warm, moist and anaerobic tract. It rapidly 
fills with food and the above conditions make it an ideal environment for 
bacteria to grow, therefore rapid colonisation occurs. A gram of caecal content 
may comprise of 400-500 species of bacteria and up to 2 billion organisms 
from 17 different bacterial families creating a microbial ecosystem (Chapman 
2001). There is a balance between the colonic bacteria and colonic 
epithelium. If this balance is altered, diarrhoea may result because the colonic 
epithelium is unable to effectively absorb sufficient quantities of water. This 
can occur for example as a result of antibiotic therapy and separately, if there 
is an immune response to the colonising bacteria, mucosal inflammations can 
occur. This results in diseases such as ulcerative colitis. Finally, if the bacteria 
cross invasively through the colonic epithelium, sepsis can develop (Chapman 
2001). 
The gallbladder acts as a reservoir for bile and holds around 20mls of bile 
juice. Bile is transported from the liver to the gallbladder via the hepatic and 
cystic duct. The main function of bile is to emulsify fats. It is released in 
response to hormones secreted by the duodenum, usually in the presence of 
meals (Stendal 1997). Bile is transported to the duodenum via the cystic and 
common bile duct. The pancreatic duct is connected at the distal region to the 
common bile duct where the united channel in most cases empties into the 
duodenum. The sphincter of Oddi is located here, the function of which is to 
regulate the entry of pancreatic and bile juice into the duodenum (Stendal 
1997). 
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The pancreas houses two major cell types; exocrine and endocrine. The 
function of the endocrine cells is the production of insulin, glucagon, and 
somatostatin which mainly regulate blood sugar levels. The exocrine cells 
produce and secrete digestive enzymes and bicarbonate ions. With regards to 
pancreatic secretion, hormonal mediators are more important than neural 
mechanisms for stimulation of pancreatic juices. 
Carbohydrates and fats are the body’s main source of energy. Most dietary 
carbohydrates are in the form of large polysaccharides or disaccharides. In 
order for these sugars to be absorbed, they must be metabolised by enzymes 
into their monosaccharide absorbable forms (Simren and Stotzer 2006). 
Glucose and fatty acids are the main substances metabolised for use by the 
Krebs cycle to produce energy. The Krebs cycle occurs within the 
mitochondria of a cell (Martini 2006). 
Monosaccharide’s have a ring-shaped structure. They are single-sugar units. 
Disaccharides are formed from two monosaccharide molecules that are 
bonded together; examples include Lactose, Sucrose and Maltose (Martini 
2006). Both monosaccharide’s and disaccharides contain only one or two 
sugar units and so are referred to as simple carbohydrates (Nix 2012). 
Polysaccharides are long chains of monosaccharide molecules. Examples 
include starch and glycogen (Martini 2006). They are referred as complex 
carbohydrates (Nix 2012). 
Because monsaccharides are single molecules, they do not need be 
metabolised and so are readily absorbed across the small intestine. 
Disaccharides on the other hand need enzymes to break the bond between 
the molecules. Examples include the lactase enzyme which metabolises 
lactose into glucose and galactose. Another example is the sucrase enzyme 
which metabolises sucrose into its monosaccharide components glucose and 
fructose.  
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As polysaccharides are more complex structures, metabolism occurs at a 
much slower rate. Because of this mechanism, energy is released over a 
longer period of time (Nix 2012). 
The physiological effects of carbohydrates apart from energy supply to the 
biological system includes; the control of blood glucose and insulin 
metabolism, satiety and gastric emptying, cholesterol and triglyceride 
metabolism, bowel function, bile acid dehydroxylation and they also affect 
colonic micoflora (FAO 1997). 
Salivary amylase begins the process of carbohydrate digestion. Mastication of 
food mixes the bolus with saliva and the enzyme amylase initiates the 
hydrolysis of starch (digestible carbohydrate). Salivary amylase is deactivated 
by the low pH of the gastric secretions within the stomach but will continue to 
work if it is in the centre of a food bolus. Gastric secretions will continue to 
diffuse polysaccharides and other food components. Some carbohydrates 
have been shown to decrease the rate of gastric emptying. These are 
carbohydrates that increase the viscosity of gastric contents and this in turn is 
associated with certain non-starch polysaccharides affecting the glycaemic 
and insulin responses as well as lowering plasma cholesterol levels. Non-
starch polysaccharides are polysaccharides associated with dietary fibre 
(cellulose, hemicellulose, pectin and gums) and oligosaccharides such as 
insulin (Schneeman 2007).  
Complex carbohydrates are digested by microbial enzymes and therefore 
have important physiological effects throughout the GI tract as they are not 
metabolised until they reach the colon. These include their water-holding 
capacity, increased viscosity within the small intestine, bile acid binding, bulk 
properties and they are also used for microbial growth in the colon. Increased 
viscosity within the small intestine has been shown to delay the absorption of 
sugar. Certain polysaccharides have also shown that they can bind or adsorb 
bile acids. These effects are associated with the ability of certain 
polysaccharides to have an effect on glucose and insulin responses as well as 
the lowering of plasma cholesterol concentrations (Schneeman 2007). 
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As the chyme enters the small intestine, the presence of protein, fat and acid 
stimulates pancreatic and bile secretions. Pancreatic amylase continues the 
hydrolysis of starch. This process of metabolism enables the monosaccharide 
end products to be absorbed by the intestinal villi. However, not all starch is 
digested, some remains in the small intestine as ‘resistant starch’. The non-
digestible carbohydrates remain intact and continue to the colon. 
Residual intestinal material including the resistant starch and non-starch 
polysaccharides enter the colon through the ileo-cecal valve. The fermentation 
of these carbohydrates by colonic bacteria produces by-products such as 
short-chain fatty acids and gases such as hydrogen, carbon and methane. 
Acetate, propionate, and butyrate are the main short chain fatty acids 
produced. Colonocytes use butyrate as an energy source, acetate is used by 
peripheral tissue and muscle cells while propionate is emptied from the portal 
blood by the liver. The non-digestible carbohydrates have another important 
role and that is in the elimination of faecal material. They do so both directly 
by increasing stool mass and indirectly by increasing microbial mass through 
supporting its growth. The major components of faecal material are water, 
microbial mass and unabsorbed/undigested food (Schneeman 2007). 
Carbohydrates historically were only considered to be required as an energy 
source, however, carbohydrate binding proteins (lectins) are found on all cell-
surface membranes (Osborn 2003). As well as bonding to proteins, 
carbohydrates also bond to lipids and play an important role in signalling 
processes on a cellular level (Boysen 2013).  
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Chapter 3 
3 Oesophageal and Gastric Cancer 
3.1 Squamous cell carcinoma and Adenocarcinoma 
 
The incidence of oesophageal and gastric cancer is increasing. This is 
particularly evident with adenocarcinoma of the oesophagus (Griffin and 
Raimes 2007). In the West, there has been a marked increase in 
adenocarcinoma of the lower oesophagus and oesophagastric junction over 
the last 20-30 years (Reynolds et al 2010). In particular, Ireland has one of the 
highest rates of oesophageal cancer in Europe, with approximately 400 new 
diagnosis each year (Reynolds 2010b). 
Oesophageal cancer is three to four times more prevalent in men than women 
(Fessler and Havrila 2012). Squamous cell carcinoma is usually located in the 
upper or middle third of the oesophageal body (Surgical Tutor 2014). These 
tumours are usually in the advanced stage upon detection and approximately 
three quarters of these tumours will have extended into the muscularis and 
lymph nodes (Griffin and Raimes 2007). For example, of 100 patients with 
oesophageal cancer, approximately 50 of these patients will have localised 
disease that can be treated with curative intent. A small minority of this group 
may not be treated aggressively because of medical co-morbidities. The five 
year survival rate is between 35-50 per cent in those patients treated with 
curative intent (Reynolds 2010b). The overall oesophageal cancer survival 
rate at five years is 22%. This includes all treatment (including curative) 
intents and all stages of oesophageal cancer (Ten year cancer audit report 
2012). 
Adenocarcinoma of the oesophagus can arise from Barrett’s oesophagus. 
This can occur when the normal squamous epithelial cells are exposed to 
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frequent or long durations of gastric acid exposure. The resulting metaplasia 
causes the normal squamous cells of the distal oesophageal body to replicate 
columnar cells, similar to those that line the stomach (Griffin and Raimes 
2007). Adenocarcinoma of the oesophagus is usually located in the lower third 
of the oesophagus.  
The risk of developing adenocarcinoma of the oesophagus as a result of 
Barrett’s oesophagus is suggested to be 30 times greater when compared to 
the general population. For example, approximately 10% of patients with 
gastro-oesophageal reflux disease will develop Barrett’s oesophagus. Of 
these Barrett’s patients, about 1% will progress to develop carcinoma. 
(Surgical Tutor 2014). Of the patients treated in St. James’s Hospital for 
oesophageal cancer, 66% of these cancers were adenocarcinoma 
morphology (Ten year cancer audit report 2012). 
If high grade Barrett’s oesophagus or very early oesophageal cancer is 
detected, then endoscopic mucosal resection and possibly radiofrequency 
ablation therapy may be performed instead of surgery (Cancer Research UK 
2014). Careful patient selection using endoscopic management appears to 
reduce morbidity and mortality rates when compared to performing an 
oesophagectomy. However, the long-term effectiveness of endoscopic 
therapy needs further evaluation (O’Farrell et al 2013). 
Obesity is thought to play a role in the development of cancer (Donohoe et al 
2014). Rates of obesity are increasing rapidly. This is reflected with 65% of 
men and 56% of women being overweight or obese in the United Kingdom. 
Adipose tissue is primarily deposited either subcutaneously or centrally 
(visceral fat). Visceral fat is thought to be more metabolically active and 
secrets adipokines and cytokines which contributes to systemic inflammation 
in addition to the expanded adipose tissue infiltrated with macrophages and 
activated T-cells. According to the World Cancer Research Fund, it is 
estimated that up to 35% of oesophageal cancers are attributable to obesity 
(World Cancer Research Fund 2007). Data on the correlation between gastric 
adenocarcinoma and obesity is limited (Donohoe et al 2014). 
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Symptoms associated with oesophageal cancer include; dysphagia, weight 
loss, hiccups, odynophagia, and a long history of reflux disease (Walsh et al 
2011). Unfortunately dysphagia is rarely a symptom of early disease. Aims to 
reduce mortality from oesophageal cancer include targeting factors such as 
smoking, obesity, diet and reflux disease, early diagnosis and better cure 
rates (Reynolds 2010b). Advances in the surgical and multimodal 
management of patients who present with oesophageal cancer may improve 
cure rates and survivorship (Croghan et al 2015). 
Adenocarcinoma of the stomach occurs in the gastric mucosa and accounts 
for approximately 90% of all malignant gastric tumours. Early gastric cancer is 
defined as a malignant tumour that is limited to the mucosa or submucosa. 
They are predominantly found within the lower two-thirds of the stomach. The 
detection of early gastric cancer can lead to a very good prognosis. (Griffin 
and Raimes 2007). 
The most commonly found factors attributing to the development of gastric 
cancer include mucosa inflammation, intestinal metaplasia of the gastric 
mucosa, polyps, chronic peptic ulcer, gastric epithelial dysplasia and more 
recently Helicobacter pylori has been linked with development of gastric 
cancer (Griffin and Raimes 2007). 
Following a distal gastrectomy for peptic ulcer disease, there is a higher risk of 
developing cancer. The majority of tumours are found at or near the stoma 
site. The gastric remnant may be associated with histological changes such 
as gastritis, polyps and atrophy. There is a two–fold risk of developing cancer 
when compared to a control group (Griffin and Raimes 2007). 
About three quarters of gastrointestinal stromal tumours (GIST) are benign. 
They are thought be composed of spindle cells with extracellular collagen. 
They are more common in women and there are often multiple tumours 
present (Griffin and Raimes 2007). 
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The overall survival rate at five years for gastric cancer is 23%.This includes 
all treatment (including curative) intents and all stages of gastric cancer. The 
five year survival rate in those patients treated with curative intent is 46% 
according to data published by St. James’s Hospital, Dublin (Ten year cancer 
audit report 2012). 
Pre-operative staging is generally carried out to evaluate the extent of the 
malignancy and to determine if there is any metastatic disease. The cancer 
cells can spread through tissue, the blood, and the lymphatic system. The 
investigations that may be carried out help determine the stage of the disease 
include; endoscopic ultrasound, computerised axial tomography (CAT) scan, 
positron emission tomography (PET) scan.  
St. James’s Hospital (National Centre for Oesophageal and Gastric Cancer 
and the National Centre for Management of Early Upper Gastrointestinal 
Mucosal Neoplasia), Dublin published a ten year cancer audit report in 2012 
outlining trends and referral patterns, measuring and monitoring of quality and 
care, complexity of treatment, as well as high quality data collection and 
statistical analysis. In relation to oesophageal and stomach cancer, there has 
been approximately 100% increase in new referrals over this 10 year period 
e.g. in 2003 there was 118 patients treated for oesophagogastric cancer 
increasing to 263 patients in 2012. Of this group, 41% of oesophageal and 
35% of gastric cancer patients had a family history of cancer. In 2012, 82 
complex major upper gastrointestinal resections were performed, 50 for 
oesophagectomy and 32 for total gastrectomy (Ten year cancer audit report 
2012). 
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3.2 Radiotherapy and Chemotherapy 
 
The management of oesophageal and gastric cancer may involve treatment 
with chemotherapy and radiotherapy. They may be given alone, combined, 
pre-surgery, post-surgery, or both.  
Oesophageal cancer is a systemic disease in a vast majority of patients, it 
requires systemic treatment. Patients treated with pre-operative 
chemotherapy alone, may have their disease down-staged but surgery is 
required for curative intent. If however, patients have pre-operative chemo-
radiotherapy, up to two thirds (depending on stage) will have a complete 
pathological response. According to data from Connolly Hospital, Dublin, one-
third of patients undergoing chemo-radiotherapy have a complete pathological 
response to their treatment (Walsh et al 2011). 
Radiotherapy administered pre-operatively (Neo-adjuvant) is given with the 
view of reducing the tumour size and reducing the risk of iatrogenic 
dissemination of tumour cells.  Post-operative radiotherapy is performed to 
eradicate disease at the resection or any suspected residual cancer cells. The 
disadvantage of post-operative radiotherapy is that the newly reconstructed GI 
segment may be subject to the full radiation dose which may compromise its 
function. 
Pre-operative chemotherapy is reported to induce early tumour regression 
and reduce the incidence of drug-resistant tumour cells. The use of 
chemotherapy post-surgery is often suggested in patients who are at a high 
risk of recurrence. It is also believed that adjuvant therapy should begin 
immediately after surgery because of the increased risk of metastases that 
occurs following the resection of the primary tumour (Griffin and Raimes 2007) 
An example of the regime of Radiotherapy and Chemotherapy given in St. 
James’s Hospital is shown in Table 3-1. 
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Table 3-1 - An Example of a Chemotherapy and Radiotherapy regime 
   Duration Dose/Drug 
Radiotherapy 
25 sessions over 5 
weeks. Mon-Fri over 
the 5 week duration 
41.4 Gy/23 Fractions 
Chemotherapy 
2 cycles starting on 
days 1 and 22 
Cisplatin80mg/m2 diluted in 1000ml 
NaCl 0.9%. Infused over 2-6 hrs. 
given day 1 
     
Mannitol 10% 500ml. Infused 
concurrently with cisplatin over 2-6 
hrs. given day 1 
     
5-Fluorouracil 1000mg/m2 diluted in 
1000ml NaCl 0.9%. infused over 24 
hours. given days 1-4 
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3.3 Oesophagectomy and Gastrectomy 
 
Not all oesophageal and gastric cancer patients will be suitable or benefit from 
GI surgery. Preoperative assessment and staging of cancer is very important 
in planning treatment options. Neoadjuvant therapy (chemotherapy and/or 
radiotherapy) usually in combination with surgical resection of the tumour is 
the most successful outcome for treating oesophageal and gastric 
malignancies. For those patients that require palliative care, treatments such 
as stenting may be used to try and alleviate symptoms of oesophageal and 
gastric cancer (Griffin and Raimes 2007). The patient’s anatomy, age, fitness, 
previous medical history and type/extent/location of the tumour all play 
important roles in the surgeons approach to each individual case. 
Resection of an oesophageal tumour is a very complicated and delicate 
surgical procedure. It often involves the removal and reconstruction of part or 
most of the oesophageal body and/or the oesophageal-gastric junction as well 
as the removal of lymph nodes. This surgical procedure is called an 
oesophagectomy. If the tumour has extended into the stomach, a partial 
gastrectomy may also need to be performed (Cancer Research UK 2014). 
Different types of oesophagectomies can be performed depending on the 
location, type and extent of the malignancy. An oesophagectomy may involve 
a total or partial resection of the oesophagus. The procedure is typically 
named after the surgeon that developed them: 
• Subtotal two stage Oesophagectomy (Ivor-Lewis). Right thoracotomy and 
abdominal incision with intra-thoracic anastomosis (RCS 2014) 
• Subtotal three-stage oesophagectomy (McKeown). Right thoracotomy and 
abdominal incision with neck incision for anastomosis (RCS 2014) 
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• Transhiatal Oesophagectomy. Abdominal incision with neck incision for 
anastomosis 
• Minimally invasive oesophagectomy (Thoracosopic +/- lapasroscopic 
oesophagectomy) 
The thoracic incision is made to mobilise the oesophagus while the abdominal 
incision is performed to prepare the stomach. Reconstruction involves 
creating a new oesophageal tube by performing an anastomosis to join the 
stomach to the healthy oesophageal remnant. The anastomosis can be 
performed via a cervical incision. In those patients with tumours in the lower 
third of the oesophageal body, a partial oesophagectomy may be performed. 
This can be carried out transhiatally using only an abdominal incision (NICE 
2011). 
Surgeons differ in their technique when performing an oesophagectomy and 
can approach the tumour via the neck, chest or abdomen. Reconstruction of 
the oesophagus using the stomach as a substitute is the preferred option as it 
involves only one anastomosis, refer to Figure 3-1 to Figure 3-3 (Griffin and 
Raimes 2007). However, a part of the small intestine or a colonic transposition 
can be performed depending on the circumstances, Figure 3-4. 
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Figure 3-1 - Oesophagectomy with stomach anastomosis  
(Cancer Research UK 2014) 
 
Figure 3-2 - Oesophagectomy with a partial gastrectomy  
(Cancer Research UK 2014) 
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Figure 3-3 - Total oesophagectomy  
(Cancer Research UK 2014) 
 
Figure 3-4 - Oesophagectomy with colonic transposition  
(Cancer Research UK 2014)  
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A gastrectomy is a surgical operation involving the removal of the stomach. It 
may involve the removal of the entire stomach (total gastrectomy) or part of 
the stomach (partial gastrectomy). 
A partial gastrectomy can involve the removal of the proximal stomach or it 
can be a distal gastric resection. A distal gastrectomy may involve the removal 
of the antrum, distal two-thirds of the stomach or distal four-fifths of the 
stomach. A total gastrectomy involves the complete removal of the stomach, 
gastroesophageal junction and pylorus. Other types of gastrectomy include a 
wedge resection, sleeve resection, and pylorus-preserving segmental 
gastrectomy. Laparoscopic partial gastric resections can also be performed. 
This approach takes more operating time but is thought to be associated with 
a faster GI recovery time (Wirtzfeld 2014). A lymphadenectomy is usually 
performed in conjunction with the gastric resection. As mentioned above, each 
case is tailored by the surgeon depending on the position of the cancer and 
the margins necessary to ensure complete removal of malignant cells. 
One of the most important aims when performing a curative gastrectomy is to 
ensure complete resection of the malignancy. It has been suggested that 
resection margins around the tumour should be >2-3cm for early gastric 
cancer and >2-6cm for advanced gastric cancer (Wirtzfeld 2014). 
The most common reconstructions following a partial gastric resection include 
the Billroth I, Billroth II, and Roux-en-Y. Billroth I (refer to Figure 3-5) 
preserves duodenal and jejunal connection by anastomosing the remnant 
stomach to the duodenal stump.  The most common complication of this 
technique is the reflux of biliary contents into the stomach causing alkaline 
gastritis (Wirtzfeld 2014). 
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Billroth II preserves the jejunal but not the duodenal connectivity by 
anastomosing the remnant stomach to the proximal jejunum. It is performed 
when Billroth I is not feasible. In addition to alkaline gastritis, patients may 
also experience malabsorption because the duodenal segment is 
compromised (Wirtzfeld 2014). As can be seen in Figure 3-6, the pancreatic 
and bile juices do not meet the stomach contents entering the small intestine 
until they flow down into the jejunum. 
Roux-en-Y (refer to Figure 3-7) involves the diversion of biliary drainage away 
from the gastric remnant. Patients may experience less reflux than if the 
techniques above were used, but dumping syndrome and gastric atony may 
be an issue in some (Wirtzfeld 2014). It is usually performed for a total 
gastrectomy. 
Alkaline reflux can be a complication following a gastrectomy, especially if the 
pyloric and/or lower oesophageal sphincter is resected. The incidence of 
developing reflux oesophagitis depends on the type of reconstructive surgery. 
The Roux-en-Y technique is associated with a lower rate of reflux 
oesophagitis. Factors that affect the incidence of developing alkaline reflux 
oesophagitis include; the length of the jejunal loop and the site where 
pancreatic and bile secretions enter the intestines. It is suggested that the 
jejunal loop should be 35-40cm but ideally over 50cm in length (Matei et al 
2010). 
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Figure 3-5 - Billroth I reconstruction for gastric carcinoma 
(GSI 2014) 
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Figure 3-6 - Billroth II reconstruction for gastric carcinoma 
(GSI 2014) 
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Figure 3-7 - Roux-en-Y reconstruction for gastric carcinoma 
(GSI 2014) 
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Any gastric resection may result in major nutritional consequences for the 
patient and impact their recovery and quality of life post-surgery (see section 
3.4). Therefore the aims of reconstruction for a gastrectomy is to perform the 
least complex anastomosis to allow adequate nutritional intake. In addition to 
this, alteration in GI physiology should be kept to a minimum, reflux of 
intestinal secretions into the oesophagus should be prevented, and the 
reconstruction should not be prone to long-term complications such as SIBO 
(Griffin and Raimes 2007). 
As with any surgical procedure, complications can occur. These may include 
general complications or those specific to the oesophageal or gastric 
resection and reconstruction. Such complications include: haemorrhage, 
anastomotic leak, intra-abdominal sepsis. Long term complications include: 
early satiety, dumping syndrome, SIBO, bile reflux and general malnutrition 
and weight loss (Griffin and Raimes 2007). 
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3.4 Nutritional consequences of upper GI surgery 
 
Surgical resection of the oesophagus or stomach for cancer may produce 
varied forms of malabsorption since the GI tract is our major source of 
nutrients (Lawrence 1977). Malnutrition following an oesophagectomy is 
common. This surgical procedure results in an altered stomach anatomy – the 
stomach is now smaller and in a different position. As a result of this, dumping 
syndrome due to rapid emptying of food into the duodenum can occur. In 
contrast, some patients may experience delayed gastric emptying because 
the vagus nerve is cut during surgery (Fessler and Havrila 2012). 
Impaired nutrition is more commonly observed after a partial or total 
gastrectomy when compared to oesophagectomy patients (Lawrence 1977). 
The stomach plays many important roles in digestion, for example it acts as a 
reservoir, mixes and grinds food, destroys ingested bacteria, secretes 
digestive juices and controls the emptying of gastric contents into the 
duodenum (DLGIP 2009). Therefore, it is not surprising that surgical 
manipulation and resection of all or part of the stomach has a major effect on 
nutritional status. 
The stomach is a complex organ and has many important functions. This 
includes its ability to accommodate by dilating in response to a meal without 
any significant rise in intragastric pressure. Another important function is the 
controlled release of food from the stomach into the small intestine. This 
allows the chyme to be mixed with pancreatic, bile and intestinal secretions at 
a rate which allows optimal digestion and absorption. An intact and nerve 
stimulated pyloric sphincter is vital to maintain this gastric emptying function. 
Therefore any gastric resection may result in significant malnutrition for the 
patient (Griffin and Raimes 2007). 
Following a gastrectomy, the impairment of fat absorption plays an important 
role in malabsorption. Impaired absorption of vitamins (e.g. vitamin B12) and 
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iron may also occur. The stores of Vitamin B12 are slowly depleted after a 
total gastrectomy but the development of megaloblastic anaemia has a 
delayed onset (6 months to 4 years for onset to appear) because the liver has 
a large store of this vitamin which delays the clinical appearance of B12 
deficiency. 
Dumping syndrome is a common complaint and one reason is thought to be 
due to the loss of pyloric function. Symptoms of dumping syndrome include 
epigastric fullness, hyperperistalsis, nausea, vomiting or diarrhoea.  Other 
non-abdominal symptoms can also occur as early as 15 minutes after 
ingestion of food such as tachycardia, sweating, weakness and measurable 
alterations in cardia output and regional blood flow (Ukleja 2006).  Dumping 
syndrome can be divided into two types; early and late. Early dumping 
syndrome occurs soon after the ingestion of a meal. It occurs because of the 
rapid emptying of the stomach contents into the intestine. Late dumping 
occurs about one or more hours after ingestion of a meal. It is caused by 
excess insulin secretion in response to the stomach’s rapid emptying into the 
small intestine, refer to Figure 3-8. (RCS 2014). 
It has been suggested by experimental investigations, that these symptoms 
occur as a result of a large volume shift into the bowel following a 
hyperosmolar meal. The large shift of fluid into the intestine is associated with 
a loss of water from the plasma, and can appear as alteration in cardiac 
output and redistribution in blood flow, which in turn affects the renal blood 
flow, the digital blood flow and intestinal blood flow (Lawrence 1977). The 
rapid entry of food into the intestine can stimulate the pancreas to release 
insulin causing hypoglycaemia. The inappropriate release of vasoactive GI 
hormones causes peripheral and splanchnic vasodilatation and vasomotor 
symptoms such as tachycardia and dizziness (Ukleja 2006).  
Low carbohydrate diets (especially simple carbohydrates) are necessary to 
reduce symptoms while increasing the intake of fibre to slow motility and 
reduce insulin peaks. Late dumping syndrome which is a consequence of 
reactive hypoglycaemia occurs 1-3 hours after a meal and approximately 25% 
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of patients with dumping syndrome will experience this late phase of 
symptoms. These symptoms include difficulty with concentration, hunger, 
decreased consciousness, perspiration and tremor (Ukleja 2006).   
 
Figure 3-8 - Pathophysiology of Dumping Syndrome 
(Kanth 2014) 
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Chapter 4 
4 Bacterial overgrowth of the small intestine 
4.1 Pathophysiology of Small Intestinal Bacterial Overgrowth 
 
Small intestinal bacterial overgrowth is usually defined as the presence of 
>105 colony forming units (CFU)/mL of bacteria in the proximal small intestine. 
It has been suggested however, that a lower colony count (e.g. >103 cfu/mL) 
may be enough to cause symptoms in an individual (DiBaise 2008). In SIBO, 
the bacterial species in the small intestine closely resembles the 300-400 
species normally present in the colonic region (Zaidel and Lin 2003). 
In healthy individuals, it is normal for small numbers of bacteria to be present 
in the stomach and small intestine. These bacteria are usually gram positive 
aerobes, anaerobes are rare. Colonic anaerobes (primarily fastidious 
anaerobes e.g. Bacteroides, anaerobic lactobacilli, and clostridia) are not 
normally found in the proximal small intestine, which contrasts with the mostly 
aerobic bacteria in this portion of the intestine (Zaidel and Lin 2003). 
Lactobacilli are less gas producing than some other bacteria such as Clostrida 
(Kumar et al 2010).  
In the distal part of the small intestine, the bacteria more commonly resemble 
that of the colon. These are mostly gram negative aerobes but with a minor 
contribution from anaerobes present (Table 4-1). This region is separated by 
the ileo-cecal valve, which acts like a barrier. At the ileocecal valve, the 
intestinal transit of luminal contents is slowed, allowing some colonic bacteria 
to move into the terminal ileum (Shelly 2009). Distal to this valve, the bacteria 
increase in number and consist mainly of anaerobes, refer to Figure 4-1 
(Simren and Stotzer 2006). Bacteria that reside in the proximal colon grow at 
a fast rate because they have a plentiful supply of dietary nutrients. This 
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results in a decrease in pH because of the vast short chain fatty acid 
production. In the distal colon, bacteria are more slow growing as substrate 
availability is lower and the pH is more neutral (Gibson and Roberfroid 1995).  
Table 4-1 - Concentration of bacteria CFU/mL (Simren and Stotzer 2006) 
 
Stomach Jejunum Ileum Caecum 
Aerobes 102-103 102-104 105-108 102-109 
Anaerobes 0 0 103-107 109-1012 
Total Count 102-103 102-104 105-108 1010-1012 
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Figure 4-1 - Normal intestinal bacterial flora 
(Vanderhoof & Pauley-Hunter 2013b) 
 
* Bacteria are not listed in quantitative order 
It must be considered that the total growth rate may consist of an overgrowth 
of gram positive bacteria.  This is mainly due to upper respiratory flora and 
this is a common finding in the small intestine of healthy elderly people. It is 
thought that this type of gram positive bacteria is not associated with 
symptoms of SIBO. In contrast, the gram negative, anaerobes and enterocci 
bacteria correlate with such symptoms. They also deconjugate bile acids (as 
discussed in more detail in Section 4.3 ‘Consequences of SIBO’), affect the 
binding capacity of intrinsic factor, and reduce the absorptive function of 
enterocytes (Simren and Stotzer 2006). 
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It is thought that each individual person has their own distinctive composition 
of colonic bacteria which appears to be affected by dietary patterns, intake of 
various nutrients and geographical region. However, it is also suggested that 
even in those patients with the same diet, the effects of ingested food on 
individual microflora composition may be very different (Mai and Morris 2014). 
The ‘Gold Standard’ diagnosis of SIBO is believed to be through the culturing 
of jejunal aspirate.  This can be defined as being positive for SIBO if the total 
growth is >104 bacteria and/or there is growth of gram negatives or anaerobes 
(Simren and Stotzer 2006). This however, is not an ideal method of diagnosis 
since the intestinal bacterial flora may be present in the more distal segment 
of the small intestine (DiBaise 2008). Technically, direct culture is limited to 
detecting SIBO in the upper 60cm of the small intestine (Nucera et al 
2005).This is further emphasised by the high rate of false negative results and 
the low reproducibility rates (Zaidel and Lin 2003). In addition to this, it is a 
costly and invasive method, many bacterial species do not grow in routine 
culture media, contamination of the endoscope and catheter can occur as it 
passes through the GI tract, and proper handling of the sample is required 
(Dukowicz et al 2007). Culturing of small intestinal aspirates can however, 
increase the detection rate of SIBO by 12% (Rusu et al 2012). Another study 
by Teo M. et al concludes from their findings that duodenal fluid aspiration and 
culture is the most accurate method of testing for SIBO with high specificity 
when compared to hydrogen breath testing. This study however, used a 
different methodology for their HBT findings (Teo et al 2004). 
There are numerous factors and ‘defence’ mechanisms involved to prevent 
SIBO, and control the bacterial population in the small intestine. The two 
major features include; gastric acid secretion which inactivates and destroys 
many organisms before they enter the proximal segment of the small intestine 
and, normal intestinal motility (especially Migrating Motor Complexes) which 
prevents stagnant activity to prohibit the attachment of ingested organisms 
within the intestinal lumen. Other factors include; immunoglobulins which 
provides adequate mucosal immunity, the ileocecal valve, and the secretion of 
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digestive enzymes by the pancreatic and billiary systems (DiBaise 2008; Syed 
2014). 
Migrating Motor Complexes (MMC’S) usually occur between meals, i.e. they 
are interdigestive. For obvious reasons, MMC’s more often occur at night. 
They result from migrating electrical complexes which cause regular pressure 
changes within the wall of the stomach and small intestine.  
The Myenteric plexus generate the MMC’s, however, many hormones 
including motilin also play an important role in MMC initiation and propagation. 
MMC’s are replaced by peristalsis and segmenting waves during a meal but 
may persist if a meal is light. They can start anywhere in the small intestine 
and travel distally down the GI tract. 
Their role is important in preventing SIBO by mechanically moving debris and 
bacteria distally, and lubricating the stomach and small intestine. This is 
particular to phase III of the MMC cycle which comprises of an uninterrupted 
band of regular contractions which occurs in the small intestine at a rate of 10-
12 min. These are forceful contractions which move the intestinal contents 
distally. This phase lasts between 2-12 minutes and occurs every 90-120 
minutes between meals (DLGIP 2009).  
A very early study by Vantrappen et al (1977) suggested that disorders of the 
interdigestive motor complex may be an important factor in the pathogenesis 
of bacterial colonisation in the small intestine (Vantrappen et al 1977). Another 
study by Stotzeer and associates, demonstrated that patients with SIBO lack 
interdigestive phase III activity in the small intestine and gastric antrum but 
have a higher motility index in the distal part of the duodenum. This may be a 
compensatory increase in motility in the distal intestine (Stotzeer et al 1996). 
Motility dysfunction post GI surgery is a common complication due to 
autonomic nervous dysfunction and GI hormone disruptions leading to a 
disruption in the MMC activity (Mochiki et al 2007).  
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GI Surgery that alters and affects the anatomy of the small intestine has 
commonly been associated with SIBO (Zaidel and Lin 2003). Other conditions 
related to the development of SIBO include: 
Stasis (Anatomic): 
• Small Bowel Diverticula 
• Surgical e.g. resections, ileal bypass, surgically created blind loops 
• Intestinal strictures 
• Crohn’s disease 
• Radiation 
• Fistulae (Zaidel and Lin 2003; Vanderhoof and Pauley-Hunter 2013b) 
Functional Factors 
• Intestinal dysmotility syndromes e.g. MMC dysfunction 
• Achlorhydria 
• Autonomic neuropathy 
• Reduction of gut associated lymphoid tissue (DiBaise 2008) 
Miscellaneous 
• Cirrhosis 
• Acid supressing medications, e.g. proton pump inihibitors, H2 receptor 
antagonists  
• Pancreatitis 
• Immune deficiency 
• Antimotility medications 
• Radiation enteritis 
• Diabetes mellitus 
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• Short bowel syndrome 
• Advanced age (DiBaise 2008; Zaidel and Lin 2003) 
Patients with Diabetes Mellitus (DM) may suffer from impaired gastrointestinal 
motility and/or gastroparesis. Therefore, DM may be a condition associated 
with the development of SIBO.  This is because poorly controlled and long-
standing diabetes can injure the enteric nervous system leading to impaired 
GI motility (Dukowicz et al 2007). 
Medications such as antidepressants and opiates can disturb the motility in 
the intestine because of their effect on muscles and nerves (Right Diagnosis 
2014). Other medications that affect the motility in the GI tract include 
anticholinergic agents, adsorbents and absorbents. The mechanism of action 
of the antimotility agents is to reduce and slow the motility and peristalsis in 
the small and large intestine (CueFLASH 2014). 
Small intestinal bacterial overgrowth is more common in the elderly population 
because of the onset of new diseases (e.g. diabetes), dietary changes, 
decreased immune function and reduction in gastric acid, and decreased 
intestinal motility. This may be caused by the consumption of a large number 
of medications that contribute to hypomotility (Syed 2014; Dukowicz et al 
2007). A number of studies have compared the prevalence of SIBO in older 
adults compared with control groups.  Parlesak et al showed that SIBO tends 
to be more prevalent (15.6%) in older patients (61-94 years of age) than in 
healthy controls (5.9%, 24-59 years of age); however there was variability in 
their methodology of testing (Parlesak et al 2003). Teo M. et al (2004) 
reported that SIBO was identified in 48% of patients in a prospective study 
looking as the possible cause of chronic diarrhoea (Teo et al 2004). 
Abnormal laboratory findings are usually only seen in patients with complex or 
severe SIBO. There may also be evidence of macrocytic anaemia due to 
malabsorption of vitamin B12 and the presence of faecal fat. These laboratory 
findings may include a decrease in thiamine and nicotinamide levels as well 
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as an increase in serum folate and vitamin K levels (Vanderhoof and Pauley-
Hunter 2013b). These findings are not diagnostic features of SIBO but are 
supportive of the diagnosis.  
Similarly, endoscopic findings are usually normal in patients with SIBO, 
however in severe cases where colitis and ileitis occurs; inflammation may be 
seen during endoscopic examination (Vanderhoof and Pauley-Hunter 2013b). 
If diarrhoea is present, stool testing may be performed to see if the cause of 
the diarrhoea is due to fat malabsorption, inflammation/infection or an osmotic 
or secretary cause. If faecal fat is present in the stool, fat malabsorption which 
may result from SIBO, celiac disease or fat maldigestion (e.g. pancreatic 
insufficiency, chronic pancreatitis) is indicated (Vanderhoof and Pauley-Hunter 
2013b). An osmotic gap can be calculated by measuring stool electrolytes and 
osmolarity. A gap of >50 mosm indicates osmotic diarrhoea which is 
associated with the ingestion of a poorly absorbed substrate such as fructose. 
A small osmotic gap and a stool weight of > 1kg/day (volume>1 L/day) 
indicates secretory diarrhoea (Fan and Sellin 2009). 
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4.2 Benefits of colonic bacteria 
 
Intestinal microflora provides an important role in metabolic and protective 
functions for the host. In terms of protective function, for example, the 
microbes assist in preventing pathogens potentially invading the intestinal 
mucosa by inhibiting attachment and subsequent entry of such pathogens into 
epithelial cells. Important metabolic functions include the fermentation of 
nondigestible carbohydrates such as starches, cellulose and pectins (large 
polysaccharides) and some oligosaccharides that avoided digestion, all of 
which provide energy to the colon (Canny and McCormick 2008). 
Colonic microbiotas perform numerous functions that benefit the digestive 
process. These functions include; the production of micronutrients, the 
metabolism and/or activation of medications, and the biotransformation of bile 
salts. These microbiota are also involved in the fermentation of indigestible 
polysacchairdes, and the prevention of luminal colonization by pathogenic 
microorganisms as mentioned above (DiBaise 2008). 
Evidence suggests that fibre degradation occurs in the colon. As there are no 
fibre enzymes, fibre enters the caecum in its unchanged state. The colonic 
bacteria ferment the fibre to short chain fatty acids, the most important of 
these are acetate, propionate and butyrate. The major source of energy for 
colonic epithelium (colonocyte) comes from butyrate (Chapman 2001).  
Bifidobacteria (major group of saccharolytic bacteria), makes up 
approximately 25% of the total bacterial population. It has many health 
benefits including, lowering blood cholesterol levels, reducing blood ammonia 
levels, producing vitamins such as B vitamins, folic acid and digestive 
enzymes such as casein, and lysozyme. It inhibits the growth of potential 
pathogens and promotes immune function against malignant cells (Gibson 
and Roberfroid 1995). 
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Intestinal bacteria also play a role in the enterohepatic circulation by 
producing enzymes which deconjugate bile acids in the colon allowing some 
reabsorption of bile across the intestinal wall (Sherwood 1996). Most however 
are eliminated in the faeces.  
Colonic bacteria can cause both beneficial and harmful effects to the host. 
Normal flora balance discourages infection by exogenous pathogens and 
overgrowth of pathogenic organisms by the production of antimicrobial 
substances or short chain fatty acids by resident flora, which inhibits the 
growth of these pathogens. Therefore antibiotics that reduce the intestinal 
flora can disrupt this balance and may result in infections or pathologic 
overgrowth (Sherwood 1996). 
Microflora in the colon also aids in the excretion process of various toxic 
substances and the flora has also been shown to stimulate immune function 
through Peyer’s patches and gut-associated lymphoid tissue. Disturbances in 
immune function can be associated with intestinal diseases such as Ulcerative 
colitis and Crohn’s disease (Mai and Morris 2004).  
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4.3 Consequences of Small Intestinal Bacterial Overgrowth 
 
One of the major effects of SIBO is the undesirable inflammatory epithelial 
changes that may result in the dampening of villi, damage to the brush border, 
and the altered cytokines/mediators which affects the absorption process 
(DiBaise 2008). Normally, in the colon, the epithelial cells and microflora form 
a barrier that protects the intestine from pathogen invasion. Impairment of this 
barrier may result in inflammatory disease see Figure 4-2 (Canny and 
McCormick 2008). 
 
Figure 4-2 - Epithelial Barrier 
(Canny and McCormick 2008) 
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Malabsorption of fats is another consequence of SIBO, this occurs because of 
bile acid deconjugation by intraluminal bacteria which – in turn, affects micelle 
formation. A significant concentration of conjugated bile acid is required for 
the formation of these micelles which transport the fat molecules across the 
intestinal lumen. Therefore, SIBO indirectly damages the absorptive mucosa 
and can lead to chronic diarrhoea which is secondary to poor fat digestion and 
absorption (Zaidel and Lin 2003).  Chronic diarrhoea is defined as greater 
than 3 stools a day for at least four weeks (Teo et al 2004). Protein and 
carbohydrate malabsorption as well as fat malabsorption may also be 
impaired as a result of bile acid deconjugation. This is as a result of 
substances such as lithocholic acid being produced which exerts a toxic effect 
on the intestinal epithelium (DiBaise 2008).  
Anaerobic bacterial utilization of Vitamin B12 within the intestinal lumen may 
result in a deficiency in this vitamin and lead to megaloblastic anaemia. 
Subsequently the bacterial synthesis may lead to an elevation in folate levels 
(DiBaise 2008). Other vitamin deficiencies may also arise as a consequence 
of SIBO and impaired micelle formation and includes deficiencies in fat-
soluble vitamins such as vitamin A (e.g. night blindness), D (osteomalacia, 
tetany), E and K (prolonged prothrombin times) this however is a rare 
occurrence (Dukowicz et al 2007). 
Most importantly, SIBO can very often affect the patient symptomatically. This 
can be both quite uncomfortable for the patient and can affect their lifestyle 
and/or quality of life. Symptoms are produced as a result of by-products 
released by the bacteria when they compete with the natural digestive 
process and metabolise, particularly carbohydrates, within the lumen of the 
small intestine. Gases such as Hydrogen, Methane and Carbon Dioxide and 
short-chain fatty acids are produced. These gases can move in both an 
antegrade and retrograde direction through the GI tract and cause non-
specific GI symptoms such as nausea, abdominal/epigastric discomfort, 
flatulence and abdominal distension. A large amount of CO2 remains in the 
small intestine and leads to bloating. In fact, these symptoms can often mimic 
Irritable Bowel Syndrome (IBS). Malabsorption of fat and poor fat digestion 
 42 
 
can lead to steatorrhoea and fat soluble vitamin deficiencies. Diarrhoea can 
also result from the short-chain fatty acid by-products. This is because they 
exert an osmotic effect and absorb water into the intestinal lumen 
(Ledochowski M and Ledochowski E 2008). Some patients with SIBO 
however may be asymptomatic (Vanderhoof and Pauley-Hunter 2013a). 
In addition, the type of bacteria present plays a role in the manifestations of 
signs and symptoms of SIBO. For example, a predominance of microbial flora 
that deconjugate bile acid  may lead to fat malabsorption or bile acid 
diarrhoea, while bacteria that prefer to metabolise carbohydrates to short 
chain fatty acids and gas may cause bloating (Dukowicz et al 2007). 
Methane slows down gut transit and may cause constipation (less than 3 
stools per week). In contrast, it has been shown that excess hydrogen 
production is linked to chronic non-specific diarrhoea and higher stool 
frequency (Kumar et al 2010). A study by Kumar S. et al showed that the 
production of methane seems to be much more common in control groups 
than in patients with IBS. This might explain the bloating symptom which is so 
frequent amongst IBS suffers since 4 atoms of hydrogen combine to produce 
1 molecule of methane (Kumar et al 2010). 
Another complication of SIBO which has been demonstrated in rats is 
bacterial translocation. This is where the bacteria move from the intestinal 
lumen across the mucosal barrier which can lead to the appearance of the 
bacteria in the mesenteric lymph nodes and visceral organs. This may lead to 
the complication of immune response activation and could be related to 
immune mediated disorders such as fibromyalgia, interstitial cystitis, and 
chronic fatigue syndrome (Petrone et al 2011).  
D-lactic acidosis can occur due to bacterial overgrowth metabolising 
carbohydrates leading to excess production of D-lactic acid.  The clinical 
presentation is characterised by recurrent episodes of unusual neurological 
manifestations and severe metabolic acidosis (Zhang et al 2003). Common 
features include slurred speech, memory loss and confusion especially after 
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high carbohydrate meals (Emmett 2013). In severe cases, colitis and ileitis 
can occur which may be evident on endoscopy. This inflammation can mimic 
a flare of Crohn’s Disease (Vanderhoof and Pauley-Hunter 2013a). 
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4.4 Small Intestinal Bacterial Overgrowth Following Surgery 
 
After surgery, the presence of adhesions may play a role in intestinal stasis 
and contribute to SIBO (Petrone et al 2011). A study by Petrone P. et al 
showed that in a group of 57 patients who were tested for SIBO, 45 patients 
had a positive result. Of these 45 patients, 82% had a history of abdominal 
surgery. They also found in their study that the mean age of SIBO patients 
was higher than that of SIBO-negative patients (57 vs 44 years). The surgery 
performed on this patient group was both laparoscopic and open surgery. The 
most frequent surgery was on the female reproductive organs (64%) followed 
by the hindgut, foregut and midgut (Petrone et al 2011).  
Small intestinal bacterial overgrowth following a gastrectomy is quite common 
because of complex reconstructions and pouches. One of the reported 
reasons is due to the loss of gastric acid, while another reason is the 
formation of blind-loops (Griffin and Raimes 2007). Impaired intestinal motility, 
reduction in gastric acid and disrupted immunologic secretions are also 
thought to contribute to the development of SIBO. Steatorrhoea and 
megablastic anaemia are the most common clinical features. It is estimated 
that dumping syndrome can occur in 15-50% of patients following 
oesophageal and gastric surgery. 
Paik et al examined a total of 77 patients for bacterial overgrowth post-
gastrectomy using a hydrogen-methane glucose breath test and they also 
performed simultaneous dumping syndrome questionnaires, serum glucose, 
hematocrit and pulse rate measurements.  The prevalence of dumping 
syndrome in this study was 46.1%. Following the ingestion of glucose, 
samples were taken every 10 minutes up to 2 hours. A positive study was 
interpreted as an increase in hydrogen or methane concentration of >12ppm 
above baseline. Of those patients that were found to be positive (77.6%) for 
SIBO, 73.7% had an increase of >12ppm by the 50 minute mark and all 59 
patients (77.6%) by the 60th minute. At the 20 minutes interval post ingestion 
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of glucose, the cumulative positivity appeared and reached plateau at 60 
minutes.  
Only 1 (1.7%) patient was positive for SIBO by methane measurement only. 
This study also found no difference in positive and negative studies regarding 
patient age, gender, time of testing post-surgery, type of gastric surgery, and 
the presence of dumping syndrome. This was also the case for BMI and 
laboratory data for nutritional status. It was noted in this paper that false 
positive results due to rapid intestinal transit should be considered. However, 
the study pointed out that even if the cut-off point for positivity was at the 30 
minute increment, 52.6% of patients would still have tested positive for SIBO 
(Paik et al 2011). 
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4.5 Management of Small Intestinal Bacterial Overgrowth 
 
Intestinal Stasis, when not associated with surgical conditions, should be 
corrected where possible e.g. the elimination or substitution of certain drugs 
known to decrease intestinal motility i.e. narcotics, benzodiazepines. In other 
cases where intestinal motility may need to be increased, prokinetic agents 
may help in this instance but it is not known how much of a benefit they have 
in aiding the treatment of patients positive for SIBO. To induce Phase III of the 
migrating motor complex (described in Section 2.1), Octreotide may be 
prescribed (Vanderhoof and Pauley-Hunter 2013a). Post antibiotic therapy, a 
low dose of erythromycin may be prescribed. This antibiotic has hormone 
properties which stimulates small intestinal peristalsis (SIG 2014; Ohio GI 
2014). 
In the management of SIBO, nutritional intervention and support plays an 
important role. For those with diagnosed or suspected SIBO, it is quite 
common in clinical practice to prescribe an antibiotic regime to reduce the 
bacterial overgrowth and reverse mucosal inflammation associated with SIBO 
(Dukowicz et al 2007). This regime will be discussed in further detail in 
Section 4.6. 
Supplements to counteract micronutrient deficiencies may be required in 
addition to short term diet restriction i.e. fat restriction to reduce steatorrhoea. 
It may be necessary to have a diet that consists of nutrients which are readily 
absorbed in the intestine, thereby leaving fewer calories for bacterial 
metabolism (Vanderhoof and Pauley-Hunter 2013a). 
As mentioned above, excessive or prolonged acid suppression may or may 
not be a contributing factor. In those patients where proton pump inhibitors 
(PPI’s) are suspected to be associated with the development of symptoms 
caused by SIBO, a reduction in PPI and/or lifestyle changes to control gastric 
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reflux may be recommended.  However, the effects of PPI’s on HBT results 
remain controversial (Dukowicz et al 2007). 
In severe cases where other management strategies have failed, surgery may 
be considered in those patients who have significant weight loss and 
diarrhoea. This may include postoperative repair of strictures and blind loops, 
intestinal tapering procedures and intestinal transplant. It may also include 
surgical correction of strictures, fistulae and diverticula (Vanderhoof and 
Pauley-Hunter 2013a; Syed 2014). The primary goal is to reduce the bacterial 
overgrowth rather than total eradication of protective microorganisms with 
antibiotics therapy (Syed 2014). Pharmacological components may be 
prescribed in combination with the antibiotic therapy to improve and 
enhance/restore small intestinal motility. 
In cases where the underlying aetiology causing SIBO is unknown, additional 
tests should be performed e.g. imaging of the small bowel to rule out 
anatomical causes of SIBO such as intestinal dilations, diverticulitis, fistulae, 
or strictures. In those with more than two episodes of SIBO with negative 
imaging and endoscopies, magnetic resonance cholangiopancreatography 
(MRCP) may be considered to rule out chronic pancreatitis (Vanderhoof and 
Pauley-Hunter 2013b).  
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4.6 Antibiotic Regime 
 
Currently, St. James’s Hospital regimen for treatment of SIBO is rifaximin 
400mg QDS for 7 days. This is given as first line antibiotic therapy to reduce 
the bacterial flora levels within the small intestine. 
Most patients respond well to appropriate antibiotic therapy (Shelly et al 
2009). Because of the diverse nature of the organism, therapy providing 
coverage for both aerobic and anaerobic organisms is recommended (DiBaise 
2008). Examples include: 
1)    Amoxicillin-clavulinic acid (30mg/kg/day)  
2) Metronidazole (20mg/kg/day) combined with a cephalosporin 
(30mg/kg/day). 
3)    Norfloxacin (800mg/day) 
4)    Rifaximin (1650mg/per day) (Vanderhoof and Pauley-Hunter 2013a). 
The antibiotic rifaximin is poorly absorbed and has shown to be effective when 
treating patients who were positive for SIBO using glucose substrate when 
compared to Chlortetracycline [(70% vs 27% respectively) (DiBaise 2008)]. 
Rifaximin treats infections only in the intestine. It passes through the stomach 
and into the intestine without being absorbed into the blood stream. Clinical 
resistance tends to be less than with other antibiotics (Vanderhoof and 
Pauley-Hunter 2013a). Another study by Vanderhoof (2013) reported in their 
literature review that 69% of patients treated with rifaximin had a clinical 
response compared with other non-rifaximin antibiotics (Vanderhoof and 
Pauley-Hunter 2013a). In contrast, a randomised trial comparing rifaximin and 
metronidazole recommended the benefits and use of metronidazole for 
treating SIBO and associated symptoms (Dukowicz et al 2007). 
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Nucrea et al suggested treating patients with a one week course of either 
rifaximin, metronidazole or fluroquinolines. In their study of 64 patients who 
were treated for SIBO, 40 (62%) showed normalization of their lactulose HBT 
following antibiotic therapy (Nucera et al 2005).  
The duration and dosing regimen of the antibiotic therapy for rifaximin varied 
amongst studies and reports. Some suggest a one week course, some a 7-10 
day course while others recommend a two week course of the antibiotic 
(Nucera et al 2005; Petrone et al 2011; Vanderhoof and Pauley-Hunter 
2013a; Dukowicz et al 2007). Variations in the dosage of rifaximin have also 
been subject to controversy. Some institutions believe that 550mg bd is 
sufficient to treat SIBO (Andreyev et al 2014). It has been suggested that 
some patients may require prolonged therapy of one to two months before a 
response is seen and symptoms improve.  Patients with recurrent symptoms 
may require continuous or cyclical antibiotic therapy i.e. first 5-10 days of 
every month (Syed 2014). Recurrence is common after treatment and tends to 
be in older adults with chronic PPI use (Vanderhoof and Pauley-Hunter 
2013a; Lauritano et al 2008).  
The use of probiotic therapy to treat SIBO has been the subject of diverse 
opinions. Outcomes using probiotic therapy is inconclusive and not generally 
recommended (Syed 2014).  
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Chapter 5 
5 Methodology 
5.1 Method of physiological measurement 
At rest and while appropriately fasting, humans do not exhale hydrogen, it is 
generated as a result of anaerobic metabolism (Eisenmann et al 2008). When 
Hydrogen is produced as a by-product of bacterial metabolism, it is readily 
and quickly absorbed across the lumen of the intestine (Simren and Stotzer 
2006). The gas enters the circulatory system and travels in the normal 
systemic flow towards the respiratory system. Here, the hydrogen gas is 
expired along with other gases through alveolar exchange. It is this expired 
hydrogen gas that is measured using the HBT device (Gastro+ Operating 
Manual 2014).  
Both glucose and lactulose are the substrates most commonly used for 
detecting SIBO. Lactulose is in some circumstances preferred as it travels the 
length of the small intestine and therefore has the ability to detect SIBO in the 
more distal parts of the small intestine. As a synthetic disaccharide, it cannot 
be metabolised into monosaccharides and absorbed as there is no naturally 
occurring lactulose enzyme present to perform this biological function. 
Therefore, the lactulose travels intact to the colon where it is metabolised by 
colonic bacteria. By this means, orocaecal transit time can be measured. In 
rare instances, there are bacteria present in the colon which are unable to 
breakdown the synthetic lactulose into fructose and galactose but these 
bacteria are still capable of producing hydrogen (Eisenmann et al 2008).  
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Glucose in general, is the most popular choice for detecting SIBO. It is readily 
absorbed and is a more sensitive substrate. The sensitivity and specificity of 
the lactulose HBT in detecting SIBO has been reported to be only 68% and 
44% and for glucose HBT 62% and 83% (Simren and Stotzer 2006).  There 
are also a number of limitations to using lactulose substrate that may result in 
false positive and false negative results (see Section 5.2). 
The glucose HBT can also been used in other applications such as in patients 
suffering from pancreatic insufficiency where it was shown be positive for 
SIBO in 40% of patients. This was also the case in patients with liver cirrhosis 
where up to 33% were found to be positive for SIBO (Eisenmann et al 2008). 
In the Gastrointestinal unit, St. James’s Hospital, the HBT is also used to test 
for lactose malabsorption, fructose malabsorption, and sucrose 
malabsorption. The dose concentration of the solution consumed and the 
length of time it takes to perform these procedures differs to that of the SIBO 
test. The HBT is a simple technique to perform, inexpensive, non-invasive, 
does not have any side effects, has several applications, and multiple studies 
can be performed using the one HBT device at the same time. 
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5.2 Values for detecting Small Intestinal Bacterial Overgrowth 
 
The fasting baseline of expired hydrogen should be <10ppm (ideally <5ppm). 
A high baseline may suggest slow intestinal transit whereby residual food is 
still being metabolised or it may be due to the presence of SIBO. This 
however is quite uncommon and is more than likely due to poor adherence of 
the pre-procedure protocol to avoid high fibre foods the day prior to the HBT.  
The glucose hydrogen breath test is considered positive if there is a clear 
peak in measured hydrogen. Again, there is vast variability amongst users as 
to what is the normal cut-off point. A majority of studies suggest that a 
hydrogen peak exceeding 10-20ppm above baseline is indicative of a positive 
glucose test (Simren and Stotzer 2006). While others suggest that any 
increase over 10ppm above baseline is considered significant (Eisenmann et 
al 2008; Croagh et al 2007). In our unit, we recommend that a rise of >12ppm 
above baseline is indicative of SIBO, refer to Figure 5-1. Some other studies 
suggest a similar protocol (Vanderhoof and Pauley-Hunter 2013b; Dukowicz 
et al 2007).  
Small intestinal bacterial overgrowth detection using lactulose is measured by 
observing for a ‘double-peak’. An initial early peak of >12ppm within the first 
60 minutes followed by a larger peak indicating that the lactulose solution has 
reached the colon, refer to Figure 5-2 (DLGIP 2009). There are limitations to 
this measurement. For example, it may be difficult to distinguish SIBO from 
colonic fermentation if there is rapid transit and the effect of lactulose itself 
must be considered as it increases intestinal transit. The detection of two 
distinguishable peaks may also result in false positives if an initial bolus 
reaches the caecum imitating the first peak before the rest of the luminal 
contents reach the caecum producing the second peak (Simren and Stotzer 
2006). Normally lactulose reaches the colon within 70-90 minutes (Eisenmann 
et al 2008). 
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Figure 5-1 - Normal and abnormal HBT using glucose substrate 
 
 
Figure 5-2 - Normal and abnormal ‘ideal’ HBT using lactulose solution 
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5.3 Factors affecting Hydrogen Breath Test analysis 
 
Smoking and exercise are restricted before and during the study. Smoking 
has the effect of raising the hydrogen concentrations while exercise lowers the 
concentration of hydrogen measured (Simren and Stotzer 2006). 
False negative results may occur in patients with gastrointestinal motor 
disorders e.g. delayed gastric emptying in which case, the HBT may be 
concluded before the substrate had the chance to reach the intestine. In 
contrast, those with rapid transit through the small intestine may yield a false 
positive result due to metabolism of the substrate by colonic bacteria. This is 
because of the reduction in the time frame where the substrate makes contact 
with the absorption mucosa. Subsequently, it is then transported to the colon 
where metabolism occurs.  
With regards with malabsorption studies as opposed to SIBO, there are 
several addition potential errors that may exist in addition to those listed 
above. These include patients that suffer from chronic pancreatitis and coeliac 
disease (Simren and Stotzer 2006). This is because the release of enzymes 
from the intestinal source is compromised leading to the inability of 
disaccharides to be broken down into monosaccharides and therefore an 
absorbable form. 
The use of fructose as a substrate may be unreliable and difficult to interpret.  
Fructose is found in many everyday foods and beverages as a sweetener. It is 
also present in fruits such as apples, peaches, cherries and pears. Absorptive 
capacity of fructose by carrier mediated facilitated diffusion varies greatly and 
tends to be dose and concentration dependant. When fructose is ingested 
with glucose, the absorption of fructose increases. However, when fructose is 
ingested with sorbitol, the absorption of fructose decreases. In dietary 
sources, both glucose and sorbitol are more likely to be found in combination 
with fructose. Therefore, HBT using fructose alone does not reflect the normal 
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dietary consumption of fructose ingestion (Simren and Stotzer 2006). Some 
units use 50g of fructose dissolved in 250mls of water, but this does not 
correspond to real physiological situations nor does it make a difference in the 
results if 25g was used instead. In addition to this, it may lead to more side 
effects during the study (Eisenmann et al 2008).  
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5.4 Limitations in Hydrogen Breath Test 
 
Glucose tends to be more sensitive in detecting SIBO compared to lactulose 
solution. However, some argue that because glucose is absorbed in the 
proximal part of the small intestine, SIBO investigation may result in a false 
negative result. Lactulose on the other hand is a synthetic sugar and therefore 
not absorbed. It travels distally, intact, to the colon where it is metabolised by 
colonic bacteria. Therefore the lactulose solution travels the entire length of 
the small intestine and in addition, has the ability to measure orocaecal transit 
time.  
A lack of hydrogen production can occur due to a predominance of intestinal 
bacteria which metabolise hydrogen themselves. Some bacteria produce 
methane from hydrogen (Dukowicz et al 2007). Bacteria that can contribute to 
a lack of hydrogen production include; acetogenic bacteria, methanogenic 
bacteria, nitrate-reducing bacteria, sulphate-reducing bacteria or it can be as a 
result from the lack of hydrogen producing bacteria within the colonic lumen 
(Ledochowski M and Ledochowski E 2008). 
The analysis of methane gas can identify SIBO is those patients who are not 
hydrogen producers. Methane breath testing can identify approximately 10% 
more patients with SIBO when compared to the glucose hydrogen breath test 
alone (Rusu et al 2012).  
HBT using fructose substrate is absolutely contraindicated in those with 
known or suspected hereditary fructose intolerance or in those with 
postprandial hypoglycaemia (Eisenmann et al 2008). 
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5.5 Gastro+ Gastrolyzer® measuring system  
The Gastro+ Gastrolyzer ® (Figure 5-3) is intended for multi-patient use in a 
clinical setting. The monitor is configured by uploading the patient’s data via a 
USB port connected to a PC which has the GastroCHART PC software 
installed. The device has a colour touch screen display and allows the user to 
view results in a list or graphical configuration. It requires three AA alkaline 
batteries to power the device. 
 
Figure 5-3 - Gastro+ Gastrolyzer® measuring system 
(Gastro+ Operating Manual 2014) 
 
The Gastro+ must be switched on in fresh air to ensure an accurate zero 
level.  It is turned on by holding the on/off button until the display lights up and 
becomes active. The unit will automatically power off after 45 minutes of 
inactivity. A D-piece is then inserted into the slot on the device, Figure 5-4. 
This D-piece is a one-way valve to prevent air being drawn back into the 
monitor. The air passes through an infection control filter that removes and 
traps >99.9% of airborne bacteria. It should be changed once a month or 
when visibly soiled as it cannot be cleaned or sterilised. Between breath tests, 
the D-piece should be removed to allow fresh air to circulate around the 
hydrogen sensor (Gastro+ Operating Manual 2014). 
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Figure 5-4 - D-piece  
(Gastro+ Operating Manual 2014) 
 
 
Figure 5-5 - Disposable mouthpiece 
(Gastro+ Operating Manual 2014) 
A single-use disposable cardboard mouthpiece is then slotted over the D-
piece and the connections firmly checked, Figure 5-5. The procedure is then 
ready to be carried out according to the guidelines in Section 5.6. 
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5.6 Hydrogen Breath Test procedure 
 
The patients arrive to the GI Function Unit for SIBO investigations following a 
strict 12hr fast. No antibiotics are permitted for at least four weeks before the 
study and no colonoscopy should be performed at least one month prior to 
this study. This is because of the reduction in the normal bacterial flora levels 
in the colon.  
Avoidance of high fibre foods the day prior to the test is another requirement 
because these high fibre foods can cause prolonged hydrogen secretion and 
elevate basal measurements (Vanderhoof and Pauley-Hunter 2013b). Other 
food products that are also not advised include onions, leeks, garlic, cabbage, 
beans or any pickled vegetable (Ledochowski M and Ledochowski E 2008). 
Laxatives, in particular lactulose should be discontinued for at least 3 days 
before HBT (Eisenmann et al 2008). Smoking and chewing gum should be 
discontinued for 12hrs prior to study. Antimotility drugs are discontinued for 
two days prior to the HBT. 
The patient is asked to perform a preliminary mouth wash with a 
chlorhexadine agent before a baseline breath sample is taken. This is to 
ensure that oral bacteria do not cause false positive results and early elevated 
measurements of expired hydrogen. The baseline breath sample should be 
0ppm, but a baseline of up to 10ppm is considered adequate to continue with 
the study (ideally <5ppm).  If the baseline is >10ppm, it might be suggested 
that the patient returns for their HBT on a subsequent day and follows a 16 
hour fast. But this is quite dependant on individual cases and circumstances.  
Following the baseline sample, the patient then ingests the appropriate 
substrate (Table 5-1) and breath samples are taken at 15 minute intervals 
over a two/three hour period. The data collected is then offloaded from the 
Gastrolyser to the computer system, printed out and saved accordingly. 
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Table 5-1 - Dose of substrate and preparation 
 
Grams Dissolved 
Glucose 50g In 250 mls hot water and allowed to cool 
Fructose 25g In 250 mls hot water and allowed to cool 
Lactulose 10g/15 mls 250 mls of room temperature water 
This volume (250 mls) of water is used because if the solution was too 
concentrated, then there would be a larger non-absorbed proportion which 
may result in a false positive test. In contrast, the smaller the concentration, 
the better the absorption rate which may lead to a false negative result 
(Ledochowski M and Ledochowski E 2008). 
Hydrogen is distributed differently depending on the subjects’ position (Shelly 
2009). During the study, the patient is asked to stay in the sitting position and 
avoid exercise/walking throughout the investigation as it may hamper 
collected samples of expired hydrogen. The HBT results are not affected by 
the presence of other subject in the procedure room (Eisenmann et al 2008). 
Even though, the HBT is a non-invasive and cost effective test when 
compared to performing intestinal aspirates, it can be quite labour-intensive 
with samples taken every 15 minutes over such long durations.  
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5.7 Hydrogen Breath Test duration and sampling times 
 
Published data on the optimal test duration is limited. A testing duration of 3 
hours has being the longest reported time frame when testing for SIBO (Grace 
et al 2012). A study from The Royal Marsden NHS Foundation Trust in 
London showed that most patients testing positive for SIBO would do so by 
the 100 minute mark. In this study, samples were taken every 20 minutes and 
methane gas analysis was also performed (Grace et al 2012). Simren and 
Stotzer (2006) documented that sampling for SIBO is usually every 15 
minutes (Simren and Stotzer 2006). 
For our investigations, we sampled at 15 minute increments over a two hour 
period. This was following the protocols of published data and to ensure no 
critical values of expired hydrogen were missed especially in those patients 
with altered GI Physiology following upper GI surgery.  
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5.8 Calibration of the Gastro+ Gastrolyzer® 
 
Calibration should be performed once a month. If the calibration icon is 
displayed on screen when the device is switched on, calibration is due. The 
Gastro+ Gastrolyzer® should be calibrated at 21oC (±4oC). If calibrated at 
lower temperatures, this may result in lower readings and vice versa.   
The calibration gas used is 100ppm hydrogen in air. The device must be 
zeroed in fresh air prior to calibration. The fine control valve (1) on the 
hydrogen gas cylinder is turned to allow the gas to flow at 0.5 litres per 
minute, Figure 5-6. The cylinder is connected to the D-piece on the monitor by 
using calibration connection equipment between the two pieces. To maintain a 
steady flow of hydrogen at this required rate of flow, the ball in the flow 
indicator on the gas cylinder is kept at the lower line (2).  The ppm value starts 
to appear on screen. 
 
Figure 5-6 - Calibration of HBT device using gas cylinder 
(Gastro+ Operating Manual 2014) 
If the final ppm reading is between 84-116ppm, the measurement will be 
accepted and automatically set in the instrument as 100ppm.  
 63 
 
5.9 How to exhale efficiently into Gastrolyzer 
 
When a breath sample is taken, the ‘breath’ icon on screen is selected. This 
initiates a countdown from 15 seconds. The patient is asked to hold their 
breath based on a resting expiratory position rather than to take a deep breath 
in (Ledochowski M and Ledochowski E 2008). The patient is asked to 
continue to hold their breath until further instruction. An audible sound is heard 
from the monitor for the final 3 seconds of the countdown which is also visible 
on screen. At the final beep, the patient is asked to insert the mouth piece into 
their mouth, close lip firmly around the disposable cardboard piece and exhale 
slowly into the device, Figure 5-7 and Figure 5-8. The patient is encouraged to 
expel the breath completely from their lungs. The ppm value will appear on 
the display. This measurement is then saved manually by pressing the ‘save’ 
icon on screen. 
In the case where patients are unable to tolerate the full breath hold, they are 
asked to inhale and hold their breath for as long as possible and then exhale 
into the mouth piece as described above.  
 
Figure 5-7 - Screen display during breath sample 
(Gastro+ Operating Manual 2014) 
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A number of patients can be simultaneously tested on this device by 
uploading all the patients’ data via GastroCHART and using the up and down 
arrows on the monitor to select each patient when taking individual samples. 
In our unit, we would not recommend performing any more than two 
simultaneous recordings. The reason for this is because it takes time for the 
hydrogen measurements to stabilise and this may result in an overlap of 
timing between patients when sampling every 15 minutes. In addition to this, if 
each or any of the patients are symptomatic with for example diarrhoea during 
their study, it would be quite unpleasant for everyone in the clinical area, 
especially if there are limited toilet facilities available.  
Following the last breath sample, the data is then downloaded onto the 
GastroCHART via a USB cable connected to the PC. The data is displayed in 
both a graphical and tabular format and lists all the patients’ details. The 
results are then printed and saved on both the local and hospital server in 
PDF. If the monitor is not likely to be used for some time, it is recommended 
that the batteries are removed. The hydrogen sensor should be replaced 
every two years. 
 
Figure 5-8 - Patient exhaling into Hydrogen Breath Test device  
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5.10 Rational of research and control group 
An audit of all referrals for Hydrogen breath testing (HBT) for small intestinal 
bacterial overgrowth (SIBO) was carried out between 2008-2011. A total 
number of 194 patients were tested for SIBO using glucose substrate and 
fructose substrate. Some patients were tested on two different occasions with 
both solutions. These patients were referred for differing reasons ranging from 
patients suffering with acute/chronic diarrhoea, steatorrhoea and/or other 
general abdominal/gastrointestinal disturbances. Patients were also referred 
post-surgery for an oesophagectomy or gastrectomy who had difficulty gaining 
weight or malabsorption issues. 
A total number of 312 HBT’s were performed on these 194 patients (124 
female vs. 70 male). Of these, 66 patients were positive (34%) for SIBO using 
glucose substrate, fructose substrate or having been tested with both 
solutions. Breath samples were taken at 20 minute intervals in accordance 
with our unit protocol (during that period) over a duration of up to 2 hours.  
The 194 patient cohorts was subdivided into two groups; a group of 22 
patients for post Gastrectomy & Oesophagectomy (G & O) and a 172 patient 
group with diagnosed or suspected Irritable Bowel Syndrome (IBS). Figure 5-9 
illustrates a flow chart of this HBT patient audit which took place in the 
Gastrointestinal function unit, St. James’s Hospital between 2008-2011 and 
their positive HBT results. 
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Figure 5-9 – GI Function SIBO Audit 2008 – 2011 
 
Figure 5-10 - Comparison between patient groups positive for SIBO 
194 patients tested for 
SIBO using HBT - 94% 
positive 
172 IBS Patients 
28% positive for SIBO 
22 post upper GI surgery 
patients 
82%  postive for SIBO 
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The post-surgical group were broken down into oesophagectomy and 
gastrectomy patients along with their corresponding positive HBT results 
(refer to table 7.1). We found that 18 out of these 22 patients were positive for 
SIBO using either glucose or fructose (82%). 
Table 5-2 - Post Oesophagectomy/Gastrectomy patients and HBT 
Results 
Surgery Type No. of patients Positive % of Positive SIBO Test 
Gastrectomy 7 6 85% 
Oesophagectomy 15 12 80% 
The glucose or fructose solution used to test for SIBO and the corresponding 
positive glucose HBT result of this post surgical group of patients is listed in 
Table 5-3. 
Table 5-3 - Post Oesophagectomy/Gastrectomy patients tested for SIBO 
Substrate No. of studies Positive Percentage 
Glucose 13 7 53% 
Fructose 22 17 77% 
Both glucose and fructose 9 6 67% 
Fructose used in detecting SIBO in post upper GI surgery patients is 
debatable as the reduced transit time could result in fructose malabsorption 
being detected as opposed to SIBO. In most literature, glucose is the 
substrate of choice for detecting SIBO. In the initial research figures below, 
fructose breath tests were undertaken as the surgical team requested these 
studies be performed to see if there was a malabsorption issue that was 
associated with the patients’ symptoms. As the research progressed, glucose 
was requested for SIBO. This was because patients found it too difficult to 
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attend for both appointments and as fructose has its limitations; glucose was 
the recommended testing substrate. 
A study from the Sheffield Teaching Hospitals NHS Trust showed similar 
results when they carried out a retrospective analysis of 447 glucose HBT’s 
performed from 1998-2010. These results demonstrated 18.8% positive result 
for SIBO when measuring both hydrogen and methane in exhaled breath 
samples (Evans et al 2012). This finding was comparable with our data above 
which showed an 8% positive SIBO finding when testing with glucose 
substrate (in the 194 patient group above) using hydrogen gas analysis only. 
In Section 5.4 ‘limitations of HBT’ it mentions that a further 10% of patients 
may be identified as being positive for SIBO when methane gas analysis is 
performed in conjunction with exhaled hydrogen. 
Based on these HBT audit results which took place in the Gastrointestinal 
function unit between 2008-2011, a comprehensive research study was 
initiated to document hydrogen breath test findings in symptomatic patients 
following an oesophagectomy or gastrectomy. This would include 
documenting the patients lifestyle habits, type of surgery, cancer morphology, 
multimodal therapy, Barrett’s histology, and post-operative complcations. 
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5.11 Patient Criteria for researched surgical group 
 
Patients used in this research study were all referred to the GI Function Unit 
by the Consultant Surgeon to establish the presence of SIBO. All patients 
referred for HBT in this group received potential curative surgery to treat 
oesophageal or gastric carcinomas.  
The majority of patients referred were symptomatic following their surgery. 
Chemotherapy and/or Radiotherapy before and/or after surgery was 
performed in some patients as part of their multimodal treatment plan.  
Patients were referred to the unit following their post-surgery clinic 
appointment. During this clinic visit, the consultant and dietician assessed the 
patient’s progress in terms of their nutritional status and clinical well-being 
following surgery.  
The exclusion criteria for this research group included those patients that: 
• Had an oesophagectomy or gastrectomy for reasons which were not related 
to a malignant tumour e.g. Achalasia 
• Had their surgery prior to 2010 
• The reconstructive part of the oesophageal or gastric surgery involved a 
colonic transposition 
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5.12 Data Collection - Patient Profiles 
A new questionnaire was devised by the Gastrointestinal Function Unit for 
patients attending for their Breath test, refer to Appendix 6. The timing 
between samples was adjusted to shorter intervals of 15 minutes to reflect the 
altered GI physiology in this group of patients. 
Initially, the main challenge was the co-operation of patients to attend for 
these tests, as they can each take up to 2hrs to perform. Most of these (68%) 
patients attending for studies lived outside the catchment area for the Hospital 
and would have to travel a lengthy distance for their procedures.  
Therefore, we co-ordinated where possible, the patients’ Hydrogen breath test 
to be followed by their clinic outpatient and dieticians appointment on the 
same day. The patients would also receive their results on this day with the 
surgical team and if necessary, prescribed antibiotics to treat the SIBO. 
A total of 106 patients were tested for SIBO post oesophagectomy and 
gastrectomy. The results of these tests are detailed in Appendix 1 
The vast majority of patients in this group, 50% (n = 53) were greater than 66 
years of age. Those patients aged 51-65 years represented 37% of this 
cohort, while those aged between 35-50 years had a 12% presence. Only one 
patient was younger than 35 years. 
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Chapter 6 
6 Data Analysis & Results 
6.1 Hydrogen Breath Test Results 
 
Of the 106 patients referred for this investigation, only 99 patients where 
included in this study. Two patients had a colonic interposition rather than a 
gastric conduit as part of their surgery. One patient refused the studies as he 
found it would be too difficult to fast and travel to the hospital. One patient 
subsequently passed away, one patient had total dysphagia and was unable 
to consume the glucose solution, and two patients were non-cancer patients. 
Of these 99 patients, 60 (61%) had a positive test. The percentage of patients 
that were positive for SIBO were broken down into those that had an 
oesophagectomy and those patient that underwent a gastrectomy. Figure 6-1 
below lists the number of patients and the corresponding percentage of 
positive HBT results. 
Table 6-1 - SIBO in post gastrectomy and oesophagectomy patients 
Surgery Type No. of patients Positive 
% of Positive 
SIBO Tests 
Gastrectomy 38 20 53% 
Oesophagectomy 61 40 66% 
 
The percentage of positive HBT results for SIBO were then analysed by the 
sugar substrate used for testing in this group of surgical patients. Table 6-2 
below shows these findings. 
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Table 6-2 - Substrate used for SIBO and their positive percentage 
response 
Substrate No. of studies Negative Positive % of Positive SIBO Tests 
Glucose 93 44 49 53% 
Fructose 54 26 28 52% 
Both glucose and fructose 48 31 17 35% 
The timeframe and corresponding positive HBT results of when these patients 
were tested for SIBO post-surgery was analysed (refer to Table 6-3). Those 
patients that were tested 7-12 months post-surgery had an 85% positive SIBO 
result. 
Table 6-3 - Duration (months) that patients were tested for SIBO post 
surgery 
Time post op (mths) No. of studies Positive % of Positive SIBO Tests 
1-6 mths 59 32 54 % 
7-12 mths 27 23 85 % 
>1 year 13 5 38 % 
  
 73 
 
6.2 Repeat Hydrogen Breath Tests post Antibiotic Therapy 
If the patients obtained a positive result for bacterial overgrowth, the surgical 
team assessed their clinical response and decided on an appropriate 
antibiotic therapy for the patient. The patient was prescribed Rifaximin 400mg 
QDS PO for seven days. A total of 12 patients that were positive for SIBO 
were prescribed antibiotics and were referred back to the GI unit for re-testing 
(refer to Table 6-4). Retesting involved having a repeat glucose HBT 
performed using the same technique as described in section 5.6. 
The remaining patients were either treated with antibiotics and clinically 
assessed for response to therapy rather than a re-test; or not treated with 
antibiotic therapy because the team recognised a clinical improvement since 
their last out-patient appointment, (patient felt symptoms are improving and/or 
patient weight had increased). For these patients, a follow-up clinic 
appointment for 6/12 months was arranged to re-assess the patient’s well-
being, and if at this stage the patient’s response was deteriorating or 
symptoms were worsening, then treatment with antibiotics would be 
considered. 
Patients that received antibiotic therapy were sent appointments to return to 
the GI unit for follow-up retesting approximately 8-10 weeks post antibiotic 
therapy.  To date a total of 12 patients returned for retesting post antibiotic 
therapy. Nine patients showed a marked improvement in symptoms and had 
gained some weight. 
The patients were retested using the same protocol and timing between 
samples. Once again, the patient would return to the clinic after their test 
ended for the team to decide on their treatment, taking into account the 
patients clinical response, their improvement if any following antibiotic 
therapy, their retest results and if their weight had increased. Seven patients 
remained positive post antibiotic therapy, but their ppm value was drastically 
reduced indicating that there was a response to antibiotic therapy. The results 
of those patients that were now negative post antibiotic treatment were 
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analysed according to weather that had underwent an oesophagectomy or 
gastrectomy (refer to Table 6-5). As these patients showed a marked 
improvement post therapy, a second dose of antibiotics was not prescribed 
but the patients were given an appointment to return to the outpatient clinic in 
6/12 months for review.  
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Table 6-4 - Patients retested post antibiotic therapy 
Patient 
No. 
Clinical 
Improvement 
PA 
Retested 
(mths) PA 
Substrate patient 
retested for 
Positive 
SIBO PA 
4 Yes some 7 Glucose, fructose Yes 
5 No  8 Glucose, Fructose Yes 
9 No 7 Glucose, fructose Yes 
17 Yes 2 
Glucose x 2, 
Fructose 
Yes first 
therapy & 
negative 2nd 
therapy 
24 Yes 2 Glucose, Fructose No 
25 Yes 2 Glucose, Fructose No 
26 Yes 2 Glucose Yes 
27 Yes initially  
2 and 10 (one 
antibiotic) 
Glucose, Fructose 
Yes on both 
retests 
28 Yes 2 Glucose, Fructose No 
37 Yes 
(1)3 weeks , 
(2) 3mths, (3 ) 
6mths 
Fructose, Glucose 
Yes  first two 
& negative 
last repeat 
39 Yes, initially  2 and 3 weeks Glucose x 2 repeats Yes for both 
50 
Some then 
symptoms 
returned for 
2nd repeat 
3 months and 
2nd repeat 2 
months post 
abx 
Glucose 
Yes both 
occasions  
PA - Post Antibiotic Therapy. Out of these 12 patients who were retested for 
SIBO, 5 were now negative for SIBO and 7 patients were still positive for 
SIBO. 
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Table 6-5 - % of patients negative for SIBO post antibiotic therapy 
Surgery Type 
No. of 
patients 
Negative post 
treatment 
% of Positive 
SIBO Tests 
Gastrectomy 4 1 25 % 
Oesophagectomy 8 4 50 % 
All patients post 
therapy 12 5 42 % 
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6.3 Comprehensive breakdown of patient data cohort 
 
A comprehensive analysis was performed to determine whether there were 
common factors amongst those patients who proved positive for SIBO. A 
detailed history of the patients treated and their diagnosis was obtained and 
scrutinised. From this group of 99 patients, 94 patients were studied. The five 
patients excluded consisted of four patients that were diagnosed with non-
cancerous GIST, and one patient that had an oesophagectomy for treatment 
of Achalasia. 
This group of patients that were tested for SIBO post-surgery for an 
oesophagectomy or gastrectomy as a result of carcinoma were categorised 
firstly by gender, age at diagnosis, BMI at diagnosis and symptoms 
experienced at diagnosis as a result of their illness/surgery.  
Breath test results for glucose were analysed in this group as it was the 
substrate that was used in 93% of subjects and is considered to be the gold 
standard. For purposes of this part of the study as it is quite specific, 
standardization and comparability of patient data was performed. The data 
collected is shown in Appendix 2. As mentioned in Section 5.10, the use of 
fructose in detecting SIBO is debatable; this is because the reduced transit 
time in this group of patients could result in the rapid emptying of the fructose 
substrate into the large intestine before it can be absorbed. It could also be as 
a result of reduced or diminished fructose transport carriers due to intestinal 
damage/inflammation. This would result in fructose malabsorption as opposed 
to SIBO. In this instance, we suggested a positive fructose result of SIBO if 
there was a very early rise in the ppm value. Therefore, it was recommended 
to the team that only glucose be performed if SIBO is to be examined. 
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6.3.1 Mean age of group and their associated HBT result 
 
The average age at diagnosis was 63.38 years. This ranged from 34 to 83 
years of age. The average age for females at diagnosis was 62.5 years (n = 
30) and for males was 63.8 years (n = 64). Those patients that had a positive 
HBT had a mean age of 62.8 years, while those with a negative HBT had a 
mean age of 63.94 years.  
There were no significant differences in the median age of patients with 
positive vs negative breath tests. Independent sample Mann Whitney U tests: 
Age: p=0.812 
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6.3.2 Symptoms Experienced 
 
There were 266 symptoms in total experienced by this patient group (refer to 
Figure 6-1). Four of these patients did not experience any symptoms what so 
ever, their diagnosis was through an incidental finding. 
The most common symptom experienced by patients was Dysphagia (n=49), 
followed by weight loss (n=37). The ‘other’ symptoms (n=13) experienced by 
these patients included: chest pain, flank pain, retro-sternal pain, waterbrash, 
back pain, cough, gastric outlet obstruction, pulsating lump in abdomen, night 
sweats, and hair loss. 
 
Figure 6-1 - Symptoms Experienced 
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6.3.3 BMI and Hydrogen Breath Test Result 
 
Some patients (n=19) that were referred from tertiary centres did not have 
their BMI documented at the time of diagnosis. BMI was documented at the 
time of diagnosis in the remaining 75 patients (56 males, 19 females). The 
average BMI in this group was 27.08. The average BMI for females was 24.38 
and for males, 28.06. 
Normal BMI was marked as being between 18.5-25, overweight 25-30, obese 
30+ and the underweight category was reported with a BMI of <18.5. Table 
6-6 lists the number of patients in each of these BMI indices and their 
corresponding positive HBT result. 
Table 6-6 - BMI of Patient Group 
BMI Index Females Males 
% of Positive 
SIBO Tests 
<18.5 3 1 5 % 
18.5-25 10 16 35 % 
25-30 3 18 28 % 
>30 4 20 32 % 
Out of 75 patients who had their BMI Documented at time of diagnosis, 60% 
were classified as being overweight or obese. In males alone, 68% were 
documented at having a BMI of >25. In the female group, 37% had a BMI of 
>25. 
A total of 70 patients with documented BMI had glucose HBT studies 
performed. Of these patients, Figure 6-2 shows the positive response rate 
with the corresponding BMI bracket for the combined female and male group. 
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Figure 6-2 - BMI and corresponding glucose result for both female and 
male group. 
 
 
Figure 6-3 - Figure BMI and positive/negative glucose Hydrogen Breath 
test.  
There was no significant difference (Pearsons Chi-square test): 0.067 
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The median BMI of patients with a positive breath test was 24.86 (range: 
17.47-42.75) versus median 29.22 (19.11-40.82) for patients with a negative 
HBT. This was significantly different (p=0.012, independent samples Mann-
Whitney U test). 
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6.3.4 Smoking and Drinking Habits 
 
Out of these 94 patients, 50 patients were ex-smoker, 15 current smokers, 27 
patients never smoked and 2 patient’s smoking history were not documented. 
Ex-drinkers were documented in 6 patient profiles, 12 patients were heavy 
drinkers, 59 patients were social drinkers, 14 non-drinkers and 3 patients 
drinking history were not documented. The number of patients and their 
smoking and drinking habits is demonstrated in Figure 6-4 below. 
 
Figure 6-4 - Smoking/Drinking History 
Seven patients did not attend for their glucose breath test. These patients 
were all tested for SIBO using fructose substrate and observed for an early 
rise in exhaled hydrogen in breath samples. There were varying reasons why 
these patients did not attend for their glucose breath test including poor 
health, travelling difficulties, challenges with fasting instructions etc. 
Therefore, 87 patients were tested for SIBO post major upper GI surgery 
using glucose substrate. 
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Out of these 87 (60 males, 27 females) patients who were tested with glucose 
substrate, 46 patients (53%) were positive for SIBO (refer to Table 6-7). 
Table 6-7 - Results of glucose breath test 
 
Positive Glucose HBT Negative Glucose HBT 
Total 53% (n=46) 47% (n=41) 
Male 43% (n=26) 57% (n=34) 
Female 74% (n=20) 26% (n=7) 
Female patients were significantly more likely to have a positive HBT than 
male patients (74.1% versus 43.33%, p=0.011). 
Ex-smokers dominated this category representing 56% of patients. Of this, ex-
smokers had a 42% positive percentage rate. Non-smokers represented 26% 
of patients and had a 73% positive result for SIBO using glucose substrate. 
Current smokers, 18% of group, had a 60% positive glucose BT result. 
Smoking history and the corresponding positive glucose HBT results are 
shown in Figure 6-5. There were 2 un-documented patient files. Therefore, 
those patients that never smoked were more likely to have a positive HBT 
(72.7%) vs. patients who were either current or ex-smokers (46.2%, p=0.047). 
The odds ratio for those patients that were smokers having a positive HBT 
versus those patients that never smoked is OR = 0.678 (95% Cl; 0.16, 2.85).  
The entire ex-smokers group smoked cigarettes only. The average amount of 
cigarettes smoked per day was 27. This value ranged from 1-100 cigarettes 
per day. The average amount of years that these patients smoked for was 
27.83 years. This ranged from 2 years right through to 50 years of smoking. 
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Figure 6-5 - Smokers/Non-Smokers/Ex-Smokers vs Positive BT Results. 
The ‘Never smoked’ group were more likely to have a positive HBT (72.7%) 
vs. patients who were either current or ex-smokers (46.2%), p=0.047. 
Social Drinking was defined by: <14 units per week for females and <21 units 
per week for males. Social drinkers were highly represented within this group, 
accounting for 65% of the total. Out of this, 53% had a positive breath result 
using glucose substrate. Non-drinker totalled 15% of the group and had a 
positive breath test result of 77%. Next were the ‘heavy drinkers’ at 12% of the 
group and had a positive result of 30%. Finally, the ‘ex-drinkers’ at 7% of the 
group had a 33% positive breath test result. Drinking habits and the 
corresponding positive breath test results are shown in Figure 6-6. ‘Non-
drinkers’ were more likely to have a positive HBT (76.9%) vs heavy drinkers 
(30%), p=0.032. The odds ratio for those patients that were drinkers having a 
positive HBT versus those patients that were non-drinkers is OR = 0.28 (95% 
Cl; 0.07, 1.12) while the odds ratio for those patients that were heavy drinkers 
having a positive HBT versus those patients that were social drinkers is OR = 
0.48 (95% Cl; 0.11, 2.13). 
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Patients who were documented as being heavy drinkers, consumed up to 50 
units of alcohol per week. Those patients who were noted as ‘ex-drinkers’ all 
had a history of alcohol dependency. 
 
Figure 6-6 - Drinking Habits vs Positive BT results.  
Non-drinkers’ were more likely to have a positive HBT (76.9%) vs heavy 
drinkers (30%), p=0.032  
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6.3.5 Disease recurrence and malignancy history 
 
Post-Surgery, 11 (13%) patients died as a result of disease recurrence. A 
further 10 (11%) patients are alive with disease while the remaining 66 (76%) 
patients have showed no evidence of disease recurrence to date. 
Of these 87 patients who were tested for SIBO using Glucose, 64 (74%) 
patients had no known previous malignancies. Malignancies were 
documented in 22 (25%) patients (refer to Figure 6-7). One patient’s 
malignancy history was not documented.  
Out of these 22 patients who had a previous history of malignancy, ten 
different cancer types were documented. 
 
Figure 6-7 - Types of Previous Malignancy 
From this group of patients who had a previous history of malignancy, two 
patients (9%) were documented as currently having disease, while two (9%) 
morbidity cases were reported from those patients who had a previous cancer 
diagnosis.  
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Figure 6-8 - Malignancy History Vs SIBO. 
Those patients with a previous history of malignancy (n=22) had a positive 
glucose breath test of 64% while those without a previous diagnosis of 
malignance had a positive glucose result of 50%. Malignancy history and the 
corresponding positive glucose HBT result is shown in Figure 6-8. Patients 
with a previously diagnosed malignancy were no more likely to have a positive 
HBT than patients without a history of malignancy (63.3% vs 50%, p=0.326). 
The odds ratio for those patients that had a history of previous malignancy 
having a positive HBT versus those patients that had no previous malignancy 
history is OR = 1.75 (95% Cl; 0.65, 4.74). 
The majority of patients who had a previous malignancy documented where 
not GI related. 
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6.3.6 Barrett’s Histology 
 
Barrett’s histology was recorded in 67 patients (refer to Figure 6-9). Out of this 
group, 43 patients had no known Barrett’s diagnosed either before or during 
evaluation of their oesophageal cancer. Patients with known Barrett’s 
oesophagus on diagnosis of cancer, accounted for 19% (n=13) of this group, 
while 16% of patients were found to have a Barrett’s oesophagus when 
undergoing evaluation for their cancer. 
 
Figure 6-9 - Barrett's Histology 
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Figure 6-10 - SIBO in patients with and without diagnosed Barrett’s 
Oesophagus 
Patients with Barrett’s oesophagus were no more likely to have a positive HBT 
in the post-operative period (45.8% vs 48.8%, p=1.00). The odds ratio for 
those patients that had documented Barrett’s Oesophagus having a positive 
HBT versus those patients that had no documented Barrett’s Oesophagus is 
OR = 0.89 (95% Cl; 0.33, 2.41). 
There were 67 patients in total with documented Barrett’s histology results. Of 
those diagnosed with Barrett’s oesophagus, 46% were positive for SIBO. 
Those patients that were documented as not having Barrett’s oesophagus 
showed a 49% positive response for SIBO using glucose substrate. This is 
demonstrated in figure Figure 6-10 above.  
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6.3.7 Tumour Site and Morphology 
 
The Oesophageal gastric junction was the most common location of tumour 
findings and this was the case in 54 patients representing 62% of this group 
(refer to Figure 6-11). This was followed by tumours located in the mid and 
distal oesophageal body, accounting for 8% and 9% of the group respectively.  
 
Figure 6-11 - Tumour Site 
 
Adenocarcinoma was diagnosed in 89% of cases (n=76). The morphology 
was not documented in two cases. Surgery was performed on all 87 patients. 
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Figure 6-12 - Cancer cell morphology Vs positive glucose study. 
The 76 patient group that were documented as having an adenocarcinoma 
showed a 54% positive result for SIBO. Those patients with diagnosed 
squamous cell carcinoma displayed a 44% positive result for SIBO (refer to 
Figure 6-12). There was no significant differences noted according to 
histological subtype (positive HBT rate in adenocarcinoma vs squamous cell 
carcinoma: 53.9% versus 44.4%, p=0.729). 
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6.3.8 Treatment type and intent 
 
Over half of this patient group (51%, n = 44) had both surgery and neo-
adjuvant therapy, while 47% (n = 40) had surgery alone as their primary 
curative treatment. Surgery and adjuvant therapy was performed in 2% (n = 2) 
of patients from this cohort. One patient who received neo-adjuvant therapy 
also went on to receive adjuvant therapy. 
Most of these surgical cases (95% n = 83) had a curative intent. However, the 
surgical outcome in 3 (4%) cases was uncertain and in one case it was 
decided to perform surgery for palliative care. Out of the 3 uncertain cases, 2 
patients now show no evidence of disease recurrence while the other patient 
is alive with disease. 
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6.3.9 Post Surgery outcomes and complications 
 
The graph shown in Figure 6-13 demonstrates the correlation between the 
type of oesophageal and gastric surgery and the associated post-surgery 
complications and breath test results.  
Transhiatal oesophagectomy and 2-stage oesophagectomy were the GI 
surgical procedure that correlated to the highest complications post 
operatively. Similarly, breath test results in 2-stage (60%) and 3-stage 
oesophagectomy’s (67%) were represented by the highest positive results.  
* Since only one patient had undergone a partial gastrectomy, this patient’s 
result is not listed in the top two groups above.  
 
Figure 6-13 - Post Surgery and BT Outcomes 
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Figure 6-14 - Surgery Type vs Glucose BT. 
 
Figure 6-14 above shows the collective surgical numbers when categorised 
into oesophagectomy or gastrectomy groupings, and their corresponding 
positive glucose HBT results. The four patients that were documents as 
having an Oesophago-Gastrectomy were placed in the gastrectomy group 
above. Those patients who underwent an oesophagectomy (n=55) showed a 
56% positive glucose result while those patients who had a gastrectomy 
(n=32) performed had a 47% positive glucose result. The proportion of 
patients who had a positive HBT did not significantly differ whether they had 
previously had an oesophagectomy versus a gastrectomy, p=0.682. 
Complications post operatively occurred in 57 patients. Of these, 5 patients 
had to return to theatre and 5 patients had a return stay in the High 
Dependency Unit (HDU) and/or Intensive Care Unit (ICU). The 30 patients 
who had no recorded complications post operatively had no further theatre or 
HDU/ICU admissions.  
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Figure 6-15 - Post – Op complication Vs SIBO detected by HBT 
 
A total of 57 patients suffered from post-surgery complications and of these 
54% were positive for SIBO using glucose substrate. SIBO was evident in 
47% of patients that did not suffer from any major post-surgery complications 
(refer to Figure 6-15). 
Patient who had post-operative complications were no more likely to have a 
positive HBT than patients who did not suffer a post-operative complication, 
p=1.0. The odds ratio for those patients experiencing post-operative 
complications having a positive HBT versus those patients with no post-
operative complications is OR = 1.36 (95% Cl; 0.56, 3.31). 
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Of the 57 patients who had post-op complications, 97 complications were 
recorded. From this, respiratory infections were the most commonly reported 
complication (23%). This was followed by cardiac arrhythmias and respiratory 
failure at 19% and 11% respectively. Figure 6-16 lists the complications 
experienced in this patient group post-surgery and the number of patients 
affected by each of these complications. 
 
Figure 6-16 - Post Surgery Complications 
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6.3.10 Chemotherapy and Radiotherapy received 
 
 
Figure 6-17 - Radiotherapy Received. 
Patients who had radiotherapy (52.5% vs 48.9%, p=0.682) were no more 
likely to have a positive HBT than patients who had surgery alone. The odds 
ratio for those patients undergoing radiotherapy having a positive HBT versus 
those patients that had no radiotherapy is OR = 1.13 (95% Cl; 0.43, 3.01). 
The radiation used in all cases was external beam (electrons) and the dose 
ranged from 13-45 Gy. 
A total of 25 patients were documents as having radiotherapy before and/or 
post-surgery. Of these, 52% were diagnosed as having SIBO. Those patients 
that did not receive radiotherapy (n=45) had a 49% positive detection rate for 
SIBO using glucose substrate. Figure 6-17 displays the radiotherapy 
treatment received and corresponding positive glucose HBT result.  
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Figure 6-18 - Chemotherapy Received. 
Patients who had chemotherapy (57.1% vs 53.1%, p=0.82) were no more 
likely to have a positive HBT than patients who had surgery alone. The odds 
ratio for those patients undergoing chemotherapy having a positive HBT 
versus those patients that had no chemotherapy is OR = 1.18 (95% Cl; 0.48, 
2.88). 
The chemotherapy regime and number of cycles administered varied widely 
amongst the patients receiving therapy.  
A total of 49 patients received chemotherapy prior to their surgery. Of these, 
57% were positive for SIBO using glucose substrate. Patients who did not 
receive any chemotherapy (n =32) showed a 53% positive response to 
glucose HBT. Those patients that received or did not receive chemotherapy 
and their corresponding positive glucose HBT results are displayed in Figure 
6-18. 
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Neither patients who had radiotherapy (52.5% vs 48.9%, p=0.682) nor 
chemotherapy (57.1% vs 53.1%, p=0.82) were more likely to have a positive 
HBT than patients who had surgery alone. 
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6.3.11 Post-Surgery Hospital Stay 
 
The length of stay in hospital following surgery varied from 8 to 67 days. As 
can be noted from Figure 6-19, the longer the length of stay in hospital 
corresponded to the highest percentage rate of post-op complications e.g. of 
the 12 patients who were in-patients for 24-27 days, 11 of these were noted to 
have post-op complications. 
The average length of stay was 20.64 days and the median was 17 days stay 
in hospital following their upper GI Surgery. The standard deviation was 
11.718 
Similarly, this was the same pattern for the glucose results, as demonstrated 
in Figure 6-19 and Figure 6-20. The longer the length of stay in hospital post-
op, the rate of positive glucose breath tests appeared to increase. However, 
there were no significant differences in the median length of stay of patients 
with positive vs negative breath tests. Independent sample Mann Whitney U 
tests: Length of stay p=0.676 
There was no apparent pattern with the association of hospital stay versus 
type of surgery. However, it was noted that the least days spent in hospital 
post-op, were occupied by those patients who had a total gastrectomy. These 
3 patients spent 8, 9 and 9 days in hospital following their surgery.  
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Figure 6-19 - Hospital stay post surgery 
 
 
Figure 6-20 - % Positive Glucose Test 
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6.3.12 Diabetic patients and Small Intestinal Bacterial Overgrowth 
 
 
Figure 6-21 - Diabetic patients and SIBO 
 
Patients without any documented diabetes (n=76; 87%) made up the majority 
of this patient cohort. These patients showed a 55% positive response for 
SIBO.  Diabetic patients (n=11) had a 36% positive glucose result (refer to 
Figure 6-21). Therefore, even though diabetes is thought to be a contributing 
factor in the development of SIBO, it did not seem to be the case from the 
data shown above in this surgical group. The odds ratio for those patients with 
diabetes having a positive HBT versus those patients with no diabetes is OR 
= 0.46 (95% Cl; 0.96, 2.80). 
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6.4 Incremental Time Sample Analysis of HBT results from 
patient cohort 
 
Seven patients did not have a glucose breath test performed. This was 
because their fructose breath test was performed first and the patient did not 
want to return for further testing. Out of those patients that were only tested 
using fructose, 7 (100%) patients were positive for small intestinal bacterial 
overgrowth. The reason it was documented as being positive for SIBO as 
opposed to Fructose malabsorption was because of the early H2 rise in 
exhaled breath in all 7 patients. These positive tests showed a rise of >12ppm 
within 60 minutes in 5 patients and within 75 minutes in one patient (refer to 
Figure 6-22). 
 
 
Figure 6-22 - Measured Breath Hydrogen (ppm) 
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A total of 87 patients had a glucose breath test performed. Table 6-8 lists the 
number of patients with positive and negative glucose HBT results. In total 46 
patients (53%) tested positive for SIBO using the glucose HBT. 
Table 6-8 - Glucose breath tests performed 
Glucose 
BT 
Total No. of 
Patients 
% of Positive 
Glucose HBT’s 
Positive 46 53% 
Negative 41 47% 
Of those 87 patients that were tested for SIBO using glucose, the time frames 
at which point the patients were positive for SIBO is listed in Table 6-9 below. 
Those patients that had their HBT performed 7-12 months post-surgery, has 
the highest positive response for SIBO at 73% 
Table 6-9 - Duration (months) that patients were tested for SIBO post 
surgery 
Time post op 
(mths) 
No. of 
studies 
Positive 
% of Positive 
Glucose HBT’s 
1-6 mths 55 25 45% 
7-12 mths 22 16 73% 
>1 year 10 5 50% 
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Table 6-10 below lists the 15 minute sampling increments and the 
corresponding positive glucose HBT result. Out of 46 patients positive for 
glucose breath tests, 96% had a positive rise within 75 minutes, 93% within 60 
minutes, 85% within 45 minutes, 59% within 30mins and 24% within 15 
minutes. The average time that patients were likely to show a positive result 
was 36.52 minutes. 
Table 6-10 - Number of patients positive for glucose BT within specific 
time frame 
Time 
(Minutes) 
No. of Patients positive for 
glucose BT 
% of Positive Glucose 
HBT’s 
15 11 24% 
30 27 59% 
45 39 85% 
60 43 93% 
75 44 96% 
90 46 100% 
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6.5 Summary 
Patient data was analysed in multiple categories ranging from body mass 
index and diagnosed malignancy, to their hospital stay and complications 
post-surgery. Table 6-11, Table 6-12 and Table 6-13 lists a summary of the 
findings discussed and displayed in chapter 8. 
Table 6-11 - Summary of patient data and their Glucose BT result 
Category Details Positive (n) Negative (n) 
Positive 
Glucose % 
 
BMI <18.5 1 0 100  
  18.5-23 19 7 73  
  25-30 9 10 47  
  >30 11 13 46  
Smoking Habit Non-smoker 16 8 76  
  Current Smoker 9 6 60  
  Ex-smoker 20 28 42  
Drinking Habit Non-Drinker 10 3 77  
  Social Drinker 29 26 53  
  Ex-Drinker 2 4 33  
  Heavy Drinker 3 7 30  
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Table 6-12 - Summary of patient data and their Glucose BT result 
Category Details Positive (n) Negative (n) 
Positive 
Glucose 
% 
 
Previous 
Malignancy 
Previous 
malignancy 
14 8 64 
 
   No malignancy hx 32 32 50  
Barrett’s Histology 
No Barrett’s 
Oesophagus 
21 22 49 
 
   
Barrett’s 
Oesophagus 
11 13 46 
 
Tumour 
Morphology 
Adenocarcinoma 41 35 54 
 
   
Squamous cell 
carcinoma 
4 5 44 
 
Surgery Type Oesophagectomy 31 24 56  
   Gastrectomy 15 17 47  
Post-op 
complications 
Complications 31 26 54 
 
   No Complications 14 16 47  
Diabetes Non-Diabetic 42 34 55  
   Diabetic 4 7 36  
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Table 6-13 - Summary of patient data and their Glucose BT result 
Category Details Positive (n) Negative (n) 
Positive Glucose 
% 
 
 Radiotherapy Radiotherapy 13 12 52  
  No Radiotherapy 21 22 49  
Chemotherapy Chemotherapy 28 21 57  
  No Chemotherapy 17 15 53  
Hospital Stay (days) 08-11 6 9 40  
  12-15 6 12 33  
  16-19 13 9 59  
  20-13 3 2 60  
  24-27 9 3 75  
  28-39 5 5 50  
  40-50 1 0 100  
  51-60 1 1 50  
  61-70 2 0 100  
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Chapter 9 
7 Discussion 
A retrospective analysis of hydrogen breath testing (HBT) was performed over 
a three year period from 2008-2011 on all patients investigated in the GI 
Function unit. A total number of 194 patients who underwent 312 Hydrogen 
breath test procedures were reviewed. Results from this audit indicated a high 
positive rate for Small Intestinal Bacterial Overgrowth (SIBO) amongst those 
patients with a history of surgery for an oesophagectomy or gastrectomy.  
This 194 patient cohort was divided into two patients groups; those referred 
with IBS symptoms (n = 172), and those referred post major upper GI surgery 
(n = 22). Patients who had a HBT performed post oesophagectomy or 
gastrectomy had an 82% positive SIBO test result. 
Based on these findings, a comprehensive analysis of hydrogen breath testing 
was carried out on a group of patients post oesophagectomy and 
gastrectomy. Exclusion criteria for this new research group included those 
patients that had complicated reconstructive surgery such as a colonic 
transposition, those patients that had their surgery for a non-malignant 
carcinoma such as a GIST or for Achalasia, and those patients that had their 
surgery prior to 2010. The timing between breath samples was reduced from 
the standard protocol of 20 minutes to 15 minutes to reflect the altered 
physiology of this patient group. A total of 106 patients were investigated for 
SIBO post oesophagectomy and gastrectomy. Of these, 99 patients were 
suitable for review in this research. Patients were investigated with both 
fructose and glucose substrate. Both of these substrates yielded similar 
results when testing for SIBO. The overall positivity for SIBO was 61% and 12 
of these patients that were prescribed a course of Rifaximin 400 mg TDS 
returned to the GI unit for retesting and least one month after their antibiotic 
therpy was completed. Of these 12 patients that were retested post therapy, 
42% were now negative for SIBO. 
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Following the results of this data, a third study group was initiated. A particular 
emphasis was placed on those patients (n=87) that had a glucose breath test 
performed. Results from these patients that had a glucose HBT performed 
was used for comprehensive analysis as the risk of false positive results was 
much lower than with fructose substrate. This is partly due to the potential 
post-surgical complication of dumping syndrome which could lead to a result 
of fructose malabsorption as opposed to SIBO. It can also be due to 
diminished fructose carriers resulting from intestinal inflammation. As part of a 
literature review conducted in this research, glucose substrate tends to be the 
standard practice in most GI units including the Royal Marsden Hospital in 
London, a specialist cancer centre.  
Clinical and surgical data was scrutinised to try and establish a more efficient 
practice for HBT procedures. This group of patients are a challenging cohort 
who have had major reconstructive surgery of the GI tract, and have gone on 
to develop malabsorption and malnutrition difficulties. This has had a major 
impact on their quality of life post-surgery. The main focus of this study was to 
establish the incidence of SIBO in this patient group and develop a streamline 
protocol. There is no published data on this aspect of SIBO to date, so by 
creating a more patient friendly protocol, progress post-surgery can be 
managed more effectively though multi-disciplinary resources. Enhancement 
of such protocols was successfully demonstrated through the findings in this 
report and is now being implemented in the GI department. 
A detailed review of this audit revealed that those patients who had a normal 
or low BMI were more positive for SIBO than those patients who were 
classified as being in the over-weight and obese categories. Similarly, those 
patients who were non-drinkers and non-smokers also had a higher positive 
glucose result compared to those patients who were current, ex or heavy 
smokers/drinkers, these trends did show a statistical significance. Lifestyle 
therefore did not seem to impact the overall glucose HBT result. Surprisingly 
there was a tendency for more normalisation of results with those patients 
who had poor lifestyle habits. 
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Diabetic patients had a notably lower positive result when compared to non-
diabetic patients. This is consistent with the other lifestyle patterns and BMI 
discussed above. In contrast, those patients who had a history of previous 
malignancy and post-op complications showed a higher result for SIBO. This 
was also the case for patients who received multimodal therapy prior to their 
surgery but these findings are not statistically significant. Studies have shown 
that chemotherapy and radiotherapy can contribute to the development of 
SIBO. This was emphasised in this research and highlights the need for a 
prospective study on SIBO in patient’s pre and post chemoradiotherapy. The 
length of hospital stay post-surgery reflects the SIBO results obtained. 
Overall, those patients who spent the least amount of time in hospital 
following surgery, i.e. a faster recovery period, were least likely to be positive 
for SIBO when compared to those patients who had a longer in-patient stay. 
Again, these trends did not show a statistical significance.  
Overall, of the 87 patients who had a glucose HBT performed, 53% were 
positive for SIBO. When broken into time frames, 45% were positive when 
tested within 1-6 months of surgery. 73% were positive for SIBO when tested 
within 7-12 months of surgery and 50% were positive when tested for SIBO 
using glucose substrate after 1 year post surgery.  As discussed in section 
2.1, MMC’s are an important contributing factor for small intestinal motility. It is 
thought that MMC disruption following surgery may take time to regulate and 
accommodate to the altered physiology. It may therefore be more beneficial to 
test patients for SIBO (unless very symptomatic) after approximately 12 
months following surgery to allow for the MMC’s to normalise and perhaps 
alter the small intestinal flora with its clearance function (Lawlor 2000). 
Table 6-10 shows the 15 minute time segments and the corresponding 
positive percentage rate for SIBO. From the data shown, by the 45th minute 
marker, 85% of those patients with SIBO showed a positive result. This 
increased to 93% by the 60th minute. All patients that were positive for SIBO, 
showed a ppm rise of >12 by 90 minutes.  The average time for patients to 
show a positive SIBO test was 36.52 minutes. Poor patient co-operation is 
one of the main disadvantages of the HBT due to time consumption, therefore 
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changing the timing protocol for the glucose HBT can be suggested. 
Currently, patients are informed that their glucose HBT can expect to take two 
hours with samples being taken at 15 minute intervals. From these findings, it 
was suggested that the HBT should take no longer than 90 minutes with the 
data trend indicating that the HBT will be terminated within 60 minutes if there 
is a rise of >12ppm. These changes have now been implemented in the GI 
Function Unit and have been captured by the local oesophageal cancer 
programme. 
False positive breath tests can occur due to rapid intestinal transit (dumping 
syndrome). Therefore an early rise (within 60 minutes) is more likely to be due 
to SIBO than fermentation by colonic bacteria. This data can be used in 
conjunction with clinical symptoms and response to antibiotic therapy to aid 
diagnosis. Non-hydrogen producers may result in false negative results. This 
is thought to be in the region of 10%. The prevalence of SIBO post-surgery 
using glucose solution is comparable to the study by Paik et al. However, the 
overall positive result for SIBO using glucose was lower in our study (53% Vs 
78%). This accountable difference may be due our inability to measure 
exhaled methane. In addition to this, the researchers used a different 
approach to their method of investigation. For example, they allowed their 
patients to smoke up to 30 minutes prior to their study which is known to 
increase hydrogen concentration levels in the blood. They also used a higher 
challenge dose of glucose (75g), took duplicate samples using different 
measurement devices and they had multiple exclusion criteria e.g. only 
gastrectomy patients with no evidence of disease recurrence for at least 6 
months were included in study. We investigated patients from as early as 4 
months following surgery. Both this study and my research showed similarities 
in the time segments for SIBO to be diagnosed. At 60 minutes post glucose 
ingestion, 100% of patients with positive HBT’s showed a positive result, while 
we reported a 94% positive response for the same time segment. There is 
limited data and research done on SIBO in patients following an 
Oesophagectomy and Gastrectomy.  
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In patients with negative Hydrogen breath tests who are symptomatic with 
chronic diarrhoea, bile acid malabsorption (BAM) should be considered as a 
cause for their symptoms. This can be examined by performing a SeHCAT 
test. SeHCAT (tauroselcholic [75selenium] acid) is a radiopharmaceutical that 
is used for detecting bile acid malabsorption. It can also be performed to 
investigate ileal function, inflammatory bowel disease, chronic diarrhoea and 
enterohepatic circulation. There are several causes of chronic diarrhoea and 
sometimes a cause is unidentifiable following numerous investigations. Bile 
acid malabsorption is one cause of chronic diarrhoea. It is not life-threatening 
but can have a major impact on quality of life. It is currently the only test used 
to diagnose bile acid malabsorption (NICE 2012). 
Recently, SeHCAT has become available to measure BAM as an investigation 
technique in this patient group in St. James’s Hospital; however there is 
limited availability of this technique throughout the hospitals in the rest of 
Ireland. There are multiple reasons for this; one being that it is not yet 
recommended by NICE and another reason is because the SeHCAT needs to 
be conducted in a nuclear medicine unit and few hospitals are equipped with 
such departments. It is also quite expensive and a time consuming technique. 
If there is no known cause of the patient’s chronic watery diarrhoea following 
other investigations, a trial therapy of bile acid sequestrants may be 
suggested. 
In St. James’s Hospital, patients are now being referred for SeHCAT if they 
are symptomatic with diarrhoea/steatorrhoea, where there has been no 
improvement or known cause of their symptoms following surgery. This 
investigation is being carried out in addition to Hydrogen breath testing in this 
patient group. A new malabsorption review chart has been devised by the 
Dietetic and surgical team for such patients to determine a cause of their 
diarrhoea/steatorrhoea (Appendix 5). 
It must be remembered that SIBO can be the cause of bile acid malabsorption 
since the bacteria can deconjugate the bile acids affecting their re- absorption 
in the ileum. Therefore in patients with chronic watery diarrhoea who 
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demonstrate a positive HBT result post oesophagectomy and gastrectomy, 
antibiotic may be trialled before the bile acid sequestrants are prescribed. This 
is because the sequenstrants can have a side effect of constipation which 
could possibly give a false impression in their symptom improvement of 
chronic diarrhoea.  
The use of HBT’s and their role in the management of patients post major 
upper GI surgery looks promising. It is still an area that requires immense 
research and development. With the expanding knowledge and commitment 
of multi-disciplinary teams and surgical expertise, the future for patients with 
difficulties post-surgery is encouraging. The GI Function Unit in St. James’s 
Hospital is determined to provide a specialist testing facility for these patients 
and will continue to promote and develop best practices for the future.  
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Chapter 10 
8 Conclusion 
Lifestyle factors including smoking and drinking habits as well as BMI had a 
statistically significant effect on the outcome of Hydrogen Breath Test (HBT) 
results. Those patients that had either a low BMI, were non-drinkers or non-
smokers were more likely to have a positive glucose HBT. 
Those patients who had a history of previous malignancy and post-operative 
complications showed a higher tendency towards a positive glucose HBT 
result, but this was not statistically significant. 
In addition to the above statement, patients who had a longer post-operative 
hospital stay following their gastrectomy or oesophagectomy also tended to 
be positive for HBT using glucose substrate. 
The percentage of patients positive for SIBO was greatest 6-12 months post-
surgery. This may be attributed by the fact that intestinal motility including 
MMC’s can take up to 12 months before it is resorted to its normal functioning 
state. 
The positive patient cohort tested using glucose substrate demonstrated 93% 
positivity for SIBO at 60 minutes. The average time for patients to show a 
positive SIBO test was 36.52 minutes. 
False positive results can occur because of dumping syndrome. Therefore a 
rise of >12ppm within 60 minutes is more likely to be from SIBO than colonic 
fermentation of the glucose substrate. 
Although some patients (up to 10%) are non-hydrogen producers, those who 
are very symptomatic with negative HBT’S should be considered for bile acid 
malabsorption investigation using SeHCAT. 
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SeHCAT is now being used in St. James’s hospital to investigate patients who 
are symptomatic with steatorrhoea/diarrhoea post-surgery. It is often 
overlooked as an investigation technique but can only be performed in a 
hospital with a nuclear medicine department. 
SIBO can be the cause of BAM, therefore it should be considered to treat a 
positive HBT with antibiotic therapy and assess clinical response before 
treatment with prescribed bile acid sequestrants commences. 
Recommendations: 
 It is recommended that the testing protocol for glucose Hydrogen 
Breath Testing is reduced from 2 hours to 60 minutes for this group of 
patients if there is no rise in hydrogen levels.  
 It is also recommended that symptomatic patients who have a negative 
Hydrogen Breath Test be referred for a SeHCAT test.  
 Further studies are recommended in a prospective group of patients to 
identify SIBO pre and post treatment with both a Hydrogen and 
Methane monitor.  
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Glossary of Terms 
Absorbent: In medical terms, are used to absorb water in the small intestine 
and colon. They are used to treat diarrhoea. 
Achlorhydria: Refers to the reduction or absence of gastric acid secretions. 
Adsorbent: (antidiarrheal) binds to caustic bacteria and eliminates them from 
the GI tract through their stool 
Aerobic: (bacteria): utilize, grow and live in an oxygenated environment. 
Aerophagia: the swallowing of air. 
Anaerobic: (bacteria): Survive in the absence of oxygen. 
Anticholinergic: a drug that blocks acetylcholine (neurotransmitter) in the 
brain. In the GI tract they are used to treat e.g. diarrhoea, muscular 
cramps/spasms 
Arrhythmia: Irregular or abnormal heart rate or rhythm 
Autonomic neuropathy: damage to the autonomic neurons. Symptoms vary 
depending on the nerves affected. In the GI tract, symptoms include 
diarrhoea, constipation, dysphagia, post-prandial nausea, early satiety etc. 
Blind loops: can be formed as a result of surgery when part of the intestine is 
by-passed. Stagnant food and slow motility makes this area a high risk 
breeding ground for bacteria. 
Casein: protein found in milk. Involved in the slow release of amino acids into 
the bloodstream 
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Chemotherapy: cancer treatment with the aim of destroying cancer cells. 
These drugs can be used to treat cancer anywhere in the body because they 
travel in the blood system. 
Cirrhosis: occurs as a result of liver disease. Irreversible fibrous scar tissue 
replaces normal liver cells. 
Colonocytes: colonic epithelial cells 
Colony forming units: (CFU) is an estimate of the number of viable bacterial 
cells in a sample per Ml. 
Co-morbidity: two or more diseases that occur simultaneously in a person with 
the initially diagnosed condition. 
Cytokines: (small proteins) are released by cells and are involved in cell 
signalling. Their primary role is cell to cell communication in immune 
responses. They can affect the behaviour of the releasing cell or other cells. 
Diverticula: an out-pouching or sac formed at a weak point in the wall of the 
gastrointestinal tract. Most commonly occurs in the colon 
Enterocytes: epithelial cells of the small intestine 
Fastidious anaerobes: organism that requires complex growth factors and 
amino acids. Can survive and grow with or without the presence of oxygen 
Fistula: abnormal connection between two body structures e.g. between an 
artery and vein, between loops of the intestine etc. 
Gastrectomy: a surgical procedure where part or all of the stomach is 
removed 
Gastric atony: stomach wall is lacking in tone resulting in muscle weakness 
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Gastroparesis: paralysis of stomach wall resulting in poor or absent gastric 
motility. 
Gram positive aerobes: retains the stain used in the gram’s staining test. Can 
help determine what antibiotic to use, if there is infection present, or type of 
further tests required to determine cause of infection. 
Hydrogen Breath Test: A technique used to measure the amount of hydrogen 
in parts per million (ppm) from a sample of exhaled air 
Hyperosmolar: high osmolarity especially of a body fluid e.g. occurs in 
dehydration, hyperglycaemia 
Hypomotility: decreased motility or movement  
Ileocecal valve: a muscle valve that separates the distal part of the small 
intestine and the proximal part of the colon. 
Immunoglobulin: an antibody used by the immune system. Produced by 
plasma cells and bind to specific antigens. 
Interstitial Cystitis: a chronic and painful bladder condition. 
Krebs cycle: part of cellular respiration providing energy that akes place within 
the mitochondria of a cell. A series of enzyme reaction with energy being 
released. 
Lymphoid tissue: makes up the lymphatic system (e.g. white blood cells, bone 
marrow) involved in immune response. Include organs such as the spleen, 
thymus and lymph nodes.  
Lysozyme: an enzyme (found in e.g. tears, salvia) that is capable of 
hydrolysing bacteria by destroying their cell walls. 
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Macrocytic anaemia: occurs when red blood cells are larger than normal and 
there is a reduction in the number of cells. Haemoglobin content is cell is often 
insufficient. This results in a reduction of oxygen reaching tissues and organs. 
Mediators: a substance or a thing (e.g. enzyme or hormone) that is released 
from cells to carry out a process 
Myenteric plexus: a nerve supply lying in the muscular wall of the 
oesophagus, stomach and intestine. Involved in the motility of the 
gastrointestinal tract. 
Neo-adjuvant: administration of therapy before the primary treatment e.g. 
chemotherapy given before a surgical procedure. 
Oesophagectomy: a surgical procedure where part or all of the oesophagus is 
removed 
Osteomalacia: softening of the bones usually because of a lack of vitamin D.  
Radiotherapy: a cancer treatment using high energy rays to control or kill 
cancer cells. 
Saccharolytic: metabolism of carbohydrates for energy. 
Short-chain fatty acids: produced in the colon as a result of fermentation. 
Butyric acid is an important short-chain fatty acid for proving energy to 
colonocytes and has anti-inflammatory/anti-carcinogenic properties. 
SIBO: Small intestinal bacterial overgrowth. A condition where bacteria inhabit 
the small intestine in great quantities and can induce a variety of symptoms 
and other health conditions in an individual.   
Tachycardia: a heart rate that is faster than the normal 60-100 bpm at rest.  
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Tetany: activation of nerve cells in the body that result in spasms or cramps of 
e.g. hands, feet, mouth. Usually due to low blood calcium or malfunctioning 
parathyroid gland. 
Viscosity: (fluid) corresponds to the ‘thickness’ of a fluid. It is a measure of the 
fluids resistance to flow.  
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Appendices 
Appendix 1 
Table A-1 - Patients tested for SIBO using Fructose and glucose solution 
Patient 
No. Age M/F 
Cancer 
patient County 
How long 
tested 
after 
surgery- 
mths 
Surgery 
type 
Positive 
SIBO 
Positive 
Glucose 
Positive/Fr
uctose 
On 
creon 
y/n 
Chmeo/rad
iation Antibiotics 
1 75 F yes Kilkenny 12 G YES YES YES NO ? NO 
2 80 M Yes Dublin 6 G NO NO NO NO ?   
3 48 M Yes Dublin 6 G NO NO NO YES none   
4 58 F Yes Dublin 24 G YES YES YES YES NONE YES 
5 64 M Yes Wicklow 10 O YES YES YES YES BOTH 2 Courses 
6 85 F Yes Dublin 7 G YES YES NO ? ?   
7 50 M Yes Laois 15 O YES N/A YES YES ?   
8 70 F Yes RIP Tiperrary 6 O YES N/A YES YES YES RIP 
9 60 M Yes Wexford 6 O YES YES YES YES ? YES 
10 53 F Yes Wexford 5 
 G          
&DO 
YES YES YES YES NO YES 
11 70 M Yes Kildare 7 O YES N/A YES ? NO   
12 67 F Yes Kerry 9 O YES N/A YES ? ?   
13 78 F Ye Dublin 18 O YES YES YES ? ?   
14 53 M Yes Dublin 12+ G NO NO NO YES CHEMO   
15 70 M Yes Dublin 24 O NO NO NO YES ?   
16 52 F No Leitrim 6 O YES YES YES YES ?   
17 70 F Yes Dublin 12+ O YES YES YES YES NONE YES x 2 
18 79 M Yes Dublin 4 G YES N/A YES YES NONE   
19 53 M Yes Dublin 12+ O NO NO NO 
TRIAL 
OFF 
YES   
20 47 M Yes Waterford 6 O YES NO YES 
TRIAL 
OFF 
CHEMO   
21 67 F Yes Wicklow 9 O YES N/A YES YES NONE   
 133 
 
Patient 
No. Age M/F 
Cancer 
patient County 
How long 
tested 
after 
surgery- 
mths 
Surgery 
type 
Positive 
SIBO 
Positive 
Glucose 
Positive/Fr
uctose 
On 
creon 
y/n 
Chmeo/rad
iation Antibiotics 
22 65 M Yes Dublin 4 O YES DNA YES YES YES YES 
23 62 M Yes Wicklow 5 O YES YES YES YES YES YES 
24 73 M Yes Galway 6 O YES NO YES YES NO YES 
25 66 M Yes Donegal 9 O YES YES YES YES NO YES 
26 54 F Yes Leitrim 12+ O YES YES NO NO YES YES 
27 60 F Yes Louth 7 G YES YES YES YES NO YES 
28 56 M Yes Dublin 7 O YES YES YES YES CHEMO YES 
29 76 M Yes Dublin   G   NOT WANT 
DON’T 
WANT 
NO     
30 54 F Tes Limerick 15 O NO NO NO NO YES   
31 59 M Yes Dublin 12 O YES YES YES YES CHEMO 
DISEASE 
RECURRENCE 
32 72 M Yes Waterford 7 O YES YES YES NO YES NO 
33 51 M Yes Wexford 7 O YES NO YES NO NONE   
34 48 M Yes Galway 7 
O & G 
&C 
YES NO YES NO NONE 
? DISEASE 
RECURRENCE 
35 83 F no Offaly 15 G YES YES NOT WANT YES ?   
36 69 M Yes Clare 7 G YES YES Yes NO CHEMO NO 
37 55 F Yes Longford 4 G YES YES YES YES Chemo? YES 
38 69 M Yes Tipperary 12+ O NO NO NO ? YES NO 
39 74 M Yes Laois 7 G YES YES NO ? YES YES 
40 42 M YES Westmeath 6 O YES YES NO NO Chemo NO 
41 62 M YES Dublin 20 O No No No ? Both No 
42 66 F YES Kildare 4 G No No No Yes No No 
43 73 M YES Wexford 14 O No No No No Both No 
44 71 M YES Waterford 12 O No No No Yes Both No 
45 59 F Yes Tipperary 6 O YES YES N/A YES NONE 
? INPATIENT 
STUDY 
46 72 M Yes Waterford 4 O YES YES NO ? BOTH ? 
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Patient 
No. Age M/F 
Cancer 
patient County 
How long 
tested 
after 
surgery- 
mths 
Surgery 
type 
Positive 
SIBO 
Positive 
Glucose 
Positive/Fr
uctose 
On 
creon 
y/n 
Chmeo/rad
iation Antibiotics 
47 49 F NO Dublin 4 O YES YES YES ? NONE ? 
48 65 male yes Westmeath 4 O No No No No None   
49 76 Male Yes Dublin 4 G No No No No Chemo RIP 
50 60 Male Yes Waterford 4 O YES Yes Yes Yes none Yes x 2 
51 79 Male Yes Longford 5 O No No No No none   
52 55 Male Yes Dublin 5 G NO NO NO ? Chemo   
53 58 Female Yes Dublin 4 O YES YES NO ? Both no 
54 72 Male Yes Longford 4 G YES NO YES ? 
Chemo 
(?&radio) 
No;  RIP 
55 40 Female Yes Dublin 7 O NO NO NO Yes Both   
56 64 Male Yes Tipperary 10 
O and 
pg? and 
C 
Yes Yes Yes Yes both No 
57 61 Female Yes Meath 4 O Yes Yes Yes ? none   
58 48 MALE ? Kilkenny 24 G No No No ? ?   
59 47 Female Yes Wexford 4 G Yes Yes No No chemo   
60 79 Male Yes Wexford 9 G Yes Yes n/a ? Chemo 
All time 
splenectomy 
61 72 Female Yes Dublin 5 G No No n/a ? Chemo 
Very poor 
technique 
62 68 Female Yes Dublin 5 O Yes No Yes No none   
63 72 Male Yes Dublin 5 O NO NO n/a ? ?   
64 75 Male Yes Kerry 8 O Yes Yes No ? radio   
65 75 Male Yes Dublin 5 G No No No None none   
66 67 Male Yes Galway 6 O No No n/a No chemo   
67 72 Female Yes Dublin 5 G Yes Yes n/a No chemo   
68 65 Male Yes Clare 5 O No No n/a No both RECURRENCE 
69 53 Male Yes Westmeath 6 O No No n/a No both RECURRENCE 
70 65 Male Yes Carlow 5 G No No n/a No none   
71 75 Male Yes Galway 6 O No No n/a No both RIP 
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Patient 
No. Age M/F 
Cancer 
patient County 
How long 
tested 
after 
surgery- 
mths 
Surgery 
type 
Positive 
SIBO 
Positive 
Glucose 
Positive/Fr
uctose 
On 
creon 
y/n 
Chmeo/rad
iation Antibiotics 
72 54 Male Yes Cavan 3 O Yes Yes n/a ? none   
73 72 Female Yes Waterford 5 G Yes Yes n/a No none   
74 46 Male Yes Sligo 7 G No No n/a n/a 
Both post 
op 
  
75 71 Male Yes Carlow 4 G Yes Yes n/a No chemo   
76 67 Male Yes Kildare 5 G No No n/a No none   
77 67 Male Yes Mayo 4 O Yes Yes n/a No none   
78 80 Male Yes Monaghan 8 G Yes Yes n/a No none   
79 61 Male Yes Sligo 7 O No No n/a No none   
80 50 Female Yes Dublin 5 G No No n/a No 
Chemo 
post-op 
  
81 60 Male Yes Dublin 5 O Yes Yes n/a No 
Chemo pre 
& post 
  
82 70 Male Yes Monaghan 6 O Yes Yes n/a Yes 
Chemo 
before 
RIP 
83 69 Male Yes Longford 27 O Yes Yes n/a No none   
84 67 Female Yes Dublin 6 O Yes Yes n/a ? chemo   
85 58 Male Yes Dublin 6 O No No n/a ? none   
86 74 Female Yes Wexford 6 G Yes Yes n/a No none   
87 51 Female Yes Dublin 5 O & G Yes Yes n/a Yes chemo Yes 
88 76 Male Yes Offaly 5 G No No n/a No none   
89 69 Male Yes Donegal 5 G Yes YES n/a No 
Both pre & 
post 
  
90 73 Female Yes Tipperary 7 O No No n/a No none   
91 74 Female Yes Wicklow 5 G & O Yes Yes n/a No chemo   
92 64 Female Yes Laois 4 O Yes Yes n/a No both   
93 59 Male Yes Dublin 6 G No No n/a No  Chemo   
94 35 Female Yes Offaly 5 G Yes Yes n/a Yes chemo Recurrence 
95 48 Male Yes Limerick 5 G No No n/a No  chemo   
96 48 Male No Dublin 5 O No No n/a ? None   
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Patient 
No. Age M/F 
Cancer 
patient County 
How long 
tested 
after 
surgery- 
mths 
Surgery 
type 
Positive 
SIBO 
Positive 
Glucose 
Positive/Fr
uctose 
On 
creon 
y/n 
Chmeo/rad
iation Antibiotics 
97 82 Male Yes Wexford 4 O No No n/a ? None Rrecurrence 
98 56 Female Yes Monaghan 4 G No No n/a ? chemo   
99 60 Female Yes Dublin 5 O Yes Yes n/a ? Both 2007 YES 
100 68 Male Yes Westmeath 4 O No No n/a No both   
101 51 Male Yes Sligo 5 O No No n/a No 
Both pre 
and post 
RECURRENCE 
102 71 Male Yes Dublin 5 G No No n/a No Chemo   
103 68 Male Yes Wicklow 5 O No No n/a No both 
A&e for dilo 
sever dysphagia 
* see notes 
104 58 Male Yes Offaly 7 O Yes Yes n/a No 
Chemo pre 
& post 
NOT TREATED 
105 75 Male Yes Wicklow 10 O Yes Yes n/a ? both   
106 57 Male Yes Wicklow 7 O Yes Yes n/a No both   
  
 137 
 
Appendix 2 
Table A-2 - Data collection from Surgical Patient Group 
Patien
t No. 
Age at 
Diagnosis M/F 
BMI at 
diagnosis Symptoms at Diagnosis 
Smoking 
status 
Alcohol 
Status 
Positive 
Glucose 
1 72 F   Heartburn, epigastric pain, dyspepsia 
Never 
smoked 
Non 
drinker YES 
2 79 M   Dysphagia, Weight loss 
Ex-
Smoker 
Social 
Drinker  NO 
3 45 M 19.11 
Anorexia,Epigastric pain,Lethargy,Epigastric discomfort,General 
malaise,Dyspepsia Smoker 
Heavy 
Drinker NO 
4 54 F   
Vomiting,Anorexia,Weight loss,,Diarrhoea,Epigastric 
bloating/fullness,Early satiety 
Never 
Smoked 
Non 
Drinker YES 
5 61 M 24.62 Dysphagia 
Not 
Document
ed 
Not 
Document
ed YES 
6 83 F 19.59 Vomiting,Nausea,,Malaena,Constipation,Weight loss 
Never 
Smoked 
Social 
Drinker YES 
7 47 M 25.69 Heartburn,Epigastric pain,Odnyophagia,Dysphagia,Reflux,Other 
Ex-
Smoker 
Social 
Drinker N/A 
8 67 F 18.01 
Anorexia,Weight loss,Epigastric pain,Dysphagia Fatigue, Chest Pain, 
Anaemia 
Never 
Smoked 
Non 
Drinker N/A 
9 58 M 23.85 Reflux,Malaena 
Never 
Smoked 
Non-
Drinker YES 
10 51 F 38.35 Other,Anaemia Flank pain 
Never 
Smoked 
Not 
Document
ed YES 
11 69 M 27.92 Reflux,Diarrhoea 
Never 
Smoked 
Social 
Drinker N/A 
12 76 F 16.77 Dysphagia,Reflux,Epigastric discomfort,Weight loss 
Never 
Smoked 
Social 
Drinker N/A 
13 73 F   Dysphagia,Anorexia,Weight loss 
Never 
Smoked 
Social 
Drinker YES 
15 67 M 31.25 Dysphagia,Hoarseness,Lethargy,Anaemia,General malaise 
Ex 
Smoker 
Social 
Drinker NO 
17 65 F 24.05 Epigastric pain,Regurgitation,Nausea,Reflux 
Ex 
Smoker 
Social 
Drinker YES 
18 78 M   Anaemia 
Never 
Smoked 
Heavy 
Drinker N/A 
19 48 M   Odnyophagia,Regurgitation,Dysphagia,Reflux 
Ex 
Smoker 
Social 
Drinker NO 
20 45 M 24.33 Weight loss,Dysphagia,Lethargy  Smoker 
Social 
Drinker NO 
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Patien
t No. 
Age at 
Diagnosis M/F 
BMI at 
diagnosis Symptoms at Diagnosis 
Smoking 
status 
Alcohol 
Status 
Positive 
Glucose 
21 65 F   None,Other picked up on routine barretts surveillance 
Never 
Smoker 
Social 
Drinker N/A 
22 63 M 21.05 Dysphagia,,Diarrhoea 
Ex 
Smoker 
Heavy 
Drinker DNA 
23 61 M 18.44 
Weight loss,Lethargy,Epigastric discomfort,Epigastric 
bloating/fullness,Abdominal pain Smoker 
Social 
Drinker YES 
24 72 M 23.1 Weight loss,Dysphagia,Reflux,Epigastric discomfort,Dyspepsia 
Ex 
Smoker 
Social 
Drinker NO 
25 64 M 31.41 None 
Ex 
Smoker 
Heavy 
Drinker YES 
26 49 F 25.81 Dysphagia Smoker 
Social 
Drinker YES 
28 54 M 29.05 Weight loss,Epigastric pain,Dysphagia 
Ex 
Smoker 
Social 
Drinker YES 
30 52 F   Weight loss,Odnyophagia 
Not 
document
ed 
Not 
document
ed NO 
31 57 M 20.58 Dysphagia,Weight loss 
Ex 
Smoker 
Social 
Drinker YES 
32 71 M 30.4 Dysphagia 
Ex 
Smoker  
Social 
Drinker YES 
33 50 M   
Haemetemesis,Nausea,Malaena,Weakness,Lethargy,Abdominal 
discomfort,Heartburn 
Never 
Smoked 
Social 
Drinker NO 
36 68 M 29.12 Weight loss,Dysphagia 
Ex 
Smoker 
Social 
drinker YES 
39 73 M 32.43 Weight loss,Dysphagia,Abdominal discomfort 
Ex 
smoker 
Non 
drinker  YES 
40 41 M 20.87 
Vomiting,Weight loss,Regurgitation,Dysphagia,Epigastric 
discomfort,Dyspepsia Smoker 
Non 
drinker YES 
41 59 M 35.38 
Weight loss,Dysphagia,Lethargy,Epigastric discomfort,Abdominal 
discomfort 
Never 
smoked 
Heavy 
drinker No 
42 65 F   Lethargy,Anaemia 
Ex 
smoker 
Social 
drinker No 
43 71 M 26.5 Weight loss,Dysphagia,Weakness,Lethargy 
Ex 
smoker 
Social 
drinker No 
44 69 M 34.23 Reflux,Anaemia 
Ex 
smoker 
Social 
drinker No 
45 59 F 28.68 Weight loss,Dysphagia 
Never 
smoked 
Non 
drinker YES 
46 71 M 31.97 Odnyophagia,Dysphagia 
Never 
smoked 
Social 
drinker YES 
48 65 M 30.07 None 
Ex Social 
No 
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Patien
t No. 
Age at 
Diagnosis M/F 
BMI at 
diagnosis Symptoms at Diagnosis 
Smoking 
status 
Alcohol 
Status 
Positive 
Glucose 
smoker drinker 
49 75 M 28.31 Reflux 
Ex 
Smoker 
Social 
Drinker No 
50 60 M 30.54 non specific chest pain 
Ex 
smoker 
Social 
Drinker Yes 
51 78 M 26.57 Weight loss,Dysphagia 
Ex 
smoker 
Social 
drinker No 
52 54 M 40.82 Heartburn,Epigastric pain,Dyspepsia 
Ex 
smoker 
Heavy 
drinker NO 
53 57 F 33.36 Weight loss,Dysphagia,Other Retrosternal pain, chest pain Smoker 
Social 
drinker YES 
54 71 M 30.07 
Haemetemesis,Malaena,Collapsed,Anaemia Opportunistic finding of 
anaemia on investigation of shoulder injury 
Ex 
smoker 
Social 
drinker NO 
55 59 F 30.04 Dysphagia,Reflux,Dyspepsia 
Ex 
smoker 
Social 
drinker NO 
56 62 M 32.49 Odnyophagia,Hiccups,Dysphagia 
Never 
smoked 
Social 
drinker Yes 
57 60 F   Dysphagia 
Ex 
smoker 
Non 
drinker Yes 
59 46 F 21.09 Epigastric pain,Reflux,Abdominal discomfort Smoker 
Non 
drinker Yes 
60 78 M 22.43 Vomiting,Weight loss,Dysphagia 
Ex 
smoker 
Non 
drinker Yes 
61 71 F 33.24 
Vomiting,Anorexia,Weight loss,Epigastric 
pain,Reflux,Diarrhoea,Lethargy,Waterbrash,Abdominal pain 
Never 
smoked 
Social 
drinker No 
62 68 F 25.64 Odnyophagia,Dysphagia,Epigastric discomfort,Abdominal discomfort 
Ex 
smoker Ex drinker No 
63 72 M 30.68 None 
Ex 
smoker 
Social 
drinker NO 
64 71 M 24.2  not documented 
Ex 
smoker 
Social 
drinker Yes 
65 73 M 31.67 Malaena,Anaemia 
Ex 
smoker 
Social 
drinker No 
66 65 M 38.05 Weight loss,Dysphagia 
Ex 
smoker 
Heavy 
drinker No 
67 71 F 21.08 Weight loss,Dysphagia 
Never 
smoked 
Social 
drinker Yes 
68 64 M 24.6 Weight loss,Dysphagia 
Ex 
smoker 
Heavy 
drinker No 
69 52 M 28.69 Heartburn,Epigastric pain,Regurgitation,Dyspepsia 
Ex 
smoker 
Social 
drinker No 
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Patien
t No. 
Age at 
Diagnosis M/F 
BMI at 
diagnosis Symptoms at Diagnosis 
Smoking 
status 
Alcohol 
Status 
Positive 
Glucose 
70 64 M 35.54 
Epigastric pain,Haemetemesis,Constipation,Flatulence,Shortness of 
breath,GI Bleed Haematemesis requiring 4 units of blood 
Ex 
smoker 
Social 
drinker No 
71 74 M 19.77 Weight loss,Dysphagia,Chest pain after eating 
Ex 
smoker Ex drinker No 
72 58 M 26.12 Epigastric pain,Dyspepsia 
Ex 
smoker 
Social 
drinker Yes 
73 68 F 24.34 
Heartburn,Regurgitation,Reflux,Lethargy,Anaemia,General 
malaise,Shortness of breath 
Never 
smoked 
Social 
drinker Yes 
74 46 M   
Vomiting,Anorexia,Weight loss,Nausea,Dysphagia,Abdominal discomfort 
Gastric outlet obstruction 
Ex 
smoker 
Social 
drinker No 
75 70 M 25.55 Dysphagia,Epigastric discomfort,Cough Back discomfort 
Ex 
smoker 
Social 
drinker Yes 
76 66 M   Anorexia,Weight loss,Early satiety,Abdominal pain Bloating, fullness Smoker 
Social 
drinker No 
77 66 M 28.06 Reflux Smoker Ex drinker Yes 
78 79 M 42.75 Epigastric discomfort 
Never 
smoked 
Social 
drinker Yes 
79 71 M   Heartburn ? Incidental pick up, presented to GP with subcutaneous lumps 
Ex 
smoker 
Social 
drinker No 
81 59 M 23.32 Weight loss,Dysphagia,Malaena,Anaemia,Abdominal discomfort 
Never 
smoked 
Social 
drinker Yes 
82 69 M 22.62 Weight loss,Odnyophagia,Dysphagia, Upper chest discomfort Smoker 
Heavy 
drinker Yes 
83 67 M   Dysphagia,,Malaena 
Ex 
smoker 
Social 
drinker Yes 
84 66 F 22.95 Heartburn,Dysphagia,Reflux Smoker 
Social 
drinker Yes 
85 56 M 31.62 Heartburn Smoker 
Heavy 
drinker No 
86 71 F 17.47 Anaemia 
Ex 
smoker Ex drinker Yes 
87 51 F 24.36 Weight loss,Regurgitation,Dysphagia,Early satiety 
Ex 
smoker 
Social 
drinker Yes 
88 75 M   Vomiting,Anorexia,Weight loss,Nausea,Epigastric discomfort 
Ex 
smoker 
Social 
drinker No 
89 68 M 27.06 Epigastric discomfort 
Ex 
smoker Ex drinker YES 
90 72 F   Reflux 
Ex 
smoker 
Non 
drinker No 
91 73 F 21.11 Vomiting,Weight loss,Dysphagia,,Anaemia,Abdominal pain Back pain 
Never 
smoker 
Social 
drinker Yes 
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Patien
t No. 
Age at 
Diagnosis M/F 
BMI at 
diagnosis Symptoms at Diagnosis 
Smoking 
status 
Alcohol 
Status 
Positive 
Glucose 
92 63 F   Odnyophagia,Dysphagia,Epigastric discomfort 
Never 
smoked 
Social 
drinker Yes 
94 34 F 19.93 
Weight loss,Nausea,Dysphagia,,Early satiety Hair loss. pulsating lump in 
abdomen 
Never 
smoked 
Social 
drinker Yes 
95 47 M 24.89 Weight loss,Epigastric pain,Belching,Odnyophagia,Dysphagia,Reflux 
Never 
smoked 
Social 
drinker No 
96 44 M 38.27 
Heartburn,Epigastric pain,,Lethargy,Anaemia,General malaise Night 
sweats 
Ex 
smoker 
Social 
drinker No 
97 82 M 26.82 Weight loss,Dysphagia 
Ex 
smoker 
Non 
drinker No 
98 55 F   Dyspepsia,Abdominal pain 
Never 
smoked 
Non 
drinker No 
99 59 F 21.71 Dysphagia,Reflux,Dyspepsia 
Ex 
smoker 
Social 
drinker Yes 
100 67 M 25.61 Weight loss,Hiccups,Dysphagia,Lethargy 
Ex 
smoker 
Social 
drinker No 
101 50 M 26.59 Vomiting,Weight loss,Epigastric pain,Dysphagia Smoker 
Heavy 
drinker No 
102 70 M 29.76 Weight loss,Dysphagia,Reflux,Anaemia,Abdominal discomfort 
Never 
smoked 
Social 
drinker No 
103 67 M 24.98 
Weight loss,Odnyophagia,Haemetemesis,Dysphagia,Anaemia Hb 7.5, 
received 2 units blood Smoker Ex drinker No 
104 57 M 25.1 Weight loss,Hiccups,Regurgitation,Dysphagia Smoker 
Heavy 
drinker Yes 
105 74 M 25.14 Weight loss,Regurgitation,Dysphagia 
Ex 
smoker 
Non 
drinker Yes 
106 56 M 33.17 Weight loss,Odnyophagia,Dysphagia,,Dyspepsia Retrosternal pain 
Ex 
smoker 
Social 
drinker Yes 
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Appendix 3 
 
Figure A-1 - Example of a Negative Glucose HBT post surgery 
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Figure A-2 - Example of a Positive Glucose HBT post surgery 
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Appendix 4 
 
Figure A-3 - Gastro+ Operating manual Specification Sheet 
 
Figure A-4 - Gastro+ Operating manual Specification Sheet 
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Appendix 5 
 
Figure A-5 - Malabsorption form for post Oesophagectomy and 
Gastrectomy Patients 
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Appendix 6  
GASTRECTOMY/OESOPHAGECTOMY QUESTIONAIRE  GI Function Unit 
 
MRN ______________________ 
 
NAME____________________________________________ 
 
DOB ___________________________ 
 
HEIGHT__________   WEIGHT__________             BMI____________ 
     (PRE AND POST SURGERY) 
DATE OF SURGERY 
 
TYPE OF SURGERY 
 
CHEMO/RADIATION 
 
REASON FOR SURGERY 
 
SYMPTOMS 
 
ONSET OF SYMPTOMS POST SURGERY 
 
SEVERITY OF SYMPTOMS 
 
ANY OTHER MEDICAL HX 
 
PRESCRIPTION MEDICATION 
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Appendix 7  
Publications and Presentations 
• Poster Presentation, Irish Society for Clinical Nutrition & Metabolism 
2nd Scientific Conference, Clyde Court Hotel, 5th and 6th March 2013 
‘Prevalence of Small Intestinal Bacterial Overgrowth Post 
Oesophagectomy’ 
 
• Poster presentations, Irish Society of Gastroenterology 50th 
Anniversary, 23rd November 2012. ‘Prevalence of Small Intestinal 
Bacterial Overgrowth Post Oesophagectomy’  
 
• Presentation ‘Hydrogen Breath Testing’ GI Physiology Day, 
Conference centre, Stewarts Hospital, Palmerstown, Friday 7th 
October 2011 
 
• Irish Society of Gastroenterology Spring meeting, Hotel Kilkenny, 
29th-30th April 2010. Poster presentation ‘Hydrogen Breath Testing. A 
two-year audit’. 
 
• Currently (2016) preparing a paper and abstract submission to the 
British Society of Gastroenterology, AGM, June  2016  
